CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | aryl phosphate |
|
Accession: | CHEBI:36943
|
browse the term
|
Synonyms: | related_synonym: | aryl phosphates |
|
|
|
G |
Acp1 |
acid phosphatase 1 |
multiple interactions increases hydrolysis |
ISO |
Benzoic Acid analog inhibits the reaction [ACP1 protein results in increased hydrolysis of nitrophenylphosphate]; Thiazolidines analog inhibits the reaction [ACP1 protein results in increased hydrolysis of nitrophenylphosphate] |
CTD |
PMID:24287560 |
|
NCBI chr 6:47,506,380...47,522,021
Ensembl chr 6:47,506,380...47,522,021
|
|
G |
Alpp |
alkaline phosphatase, placental |
increases chemical synthesis |
ISO |
ALPP protein results in increased chemical synthesis of nitrophenylphosphate |
CTD |
PMID:1495895 |
|
NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606
|
|
G |
Dusp23 |
dual specificity phosphatase 23 |
decreases phosphorylation multiple interactions |
ISO |
DUSP23 protein results in decreased phosphorylation of nitrophenylphosphate Edetic Acid inhibits the reaction [DUSP23 protein results in decreased phosphorylation of nitrophenylphosphate]; Ethylmaleimide inhibits the reaction [DUSP23 protein results in decreased phosphorylation of nitrophenylphosphate]; Vanadates inhibits the reaction [DUSP23 protein results in decreased phosphorylation of nitrophenylphosphate] |
CTD |
PMID:15147733 |
|
NCBI chr13:85,098,792...85,099,984
Ensembl chr13:85,097,899...85,100,093
|
|
G |
Pgp |
phosphoglycolate phosphatase |
decreases phosphorylation |
ISO |
PGP protein results in decreased phosphorylation of nitrophenylphosphate analog |
CTD |
PMID:24338473 |
|
NCBI chr10:13,495,232...13,497,858
Ensembl chr10:13,494,291...13,497,858
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
multiple interactions increases hydrolysis |
ISO |
Benzoic Acid analog inhibits the reaction [PTPN1 protein results in increased hydrolysis of nitrophenylphosphate]; Thiazolidines analog inhibits the reaction [PTPN1 protein results in increased hydrolysis of nitrophenylphosphate] |
CTD |
PMID:24287560 |
|
NCBI chr 3:156,638,811...156,687,503
Ensembl chr 3:156,638,769...156,687,504
|
|
G |
Ptpn2 |
protein tyrosine phosphatase, non-receptor type 2 |
increases hydrolysis multiple interactions |
ISO |
PTPN2 protein results in increased hydrolysis of nitrophenylphosphate Benzoic Acid analog inhibits the reaction [PTPN2 protein results in increased hydrolysis of nitrophenylphosphate]; Thiazolidines analog inhibits the reaction [PTPN2 protein results in increased hydrolysis of nitrophenylphosphate] |
CTD |
PMID:24287560 |
|
NCBI chr18:61,229,012...61,294,662
Ensembl chr18:61,229,014...61,294,627
|
|
|
G |
Aadac |
arylacetamide deacetylase |
multiple interactions |
ISO |
bis(4-nitrophenyl)phosphate inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin]; bis(4-nitrophenyl)phosphate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; bis(4-nitrophenyl)phosphate inhibits the reaction [AADAC protein results in decreased acetylation of rifapentine] |
CTD |
PMID:21856291 |
|
NCBI chr 2:144,163,436...144,186,086
Ensembl chr 2:144,135,319...144,174,734
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
bis(4-nitrophenyl)phosphate inhibits the reaction [ABCB1A protein affects the metabolism of irinotecan]; bis(4-nitrophenyl)phosphate inhibits the reaction [ABCB1A protein affects the stability of Everolimus] |
CTD |
PMID:24727322 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
multiple interactions |
ISO |
bis(4-nitrophenyl)phosphate inhibits the reaction [ABCB1B protein affects the metabolism of irinotecan]; bis(4-nitrophenyl)phosphate inhibits the reaction [ABCB1B protein affects the stability of Everolimus] |
CTD |
PMID:24727322 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
bis(4-nitrophenyl)phosphate inhibits the reaction [ABCG2 protein affects the metabolism of irinotecan]; bis(4-nitrophenyl)phosphate inhibits the reaction [ABCG2 protein affects the stability of Everolimus] |
CTD |
PMID:24727322 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Alb |
albumin |
multiple interactions |
EXP ISO |
bis(4-nitrophenyl)phosphate inhibits the reaction [ALB protein results in increased hydrolysis of Carbaryl]; bis(4-nitrophenyl)phosphate inhibits the reaction [ALB protein results in increased hydrolysis of Methiocarb] |
CTD |
PMID:27665777 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Ces1d |
carboxylesterase 1D |
decreases activity |
ISO |
bis(4-nitrophenyl)phosphate results in decreased activity of CES1 protein |
CTD |
PMID:23123248 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2h |
carboxylesterase 2H |
decreases activity |
ISO |
bis(4-nitrophenyl)phosphate results in decreased activity of CES2 protein |
CTD |
PMID:23123248 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
bis(4-nitrophenyl)phosphate inhibits the reaction [N-acetyl-S-pentachloro-1,3-butadienylcysteine results in decreased activity of GSR protein] |
CTD |
PMID:2360207 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
|
G |
Adcy3 |
adenylate cyclase 3 |
increases expression |
ISO |
2-ethylhexyldiphenylphosphate results in increased expression of ADCY3 mRNA |
CTD |
PMID:26794138 |
|
NCBI chr 6:27,100,089...27,203,686
Ensembl chr 6:27,124,828...27,203,686
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
ISO |
2-ethylhexyldiphenylphosphate results in increased expression of ADIPOQ mRNA |
CTD |
PMID:31812418 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adm |
adrenomedullin |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of ADM mRNA |
CTD |
PMID:33367866 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Adm2 |
adrenomedullin 2 |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of ADM2 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr 7:120,393,219...120,394,965
Ensembl chr 7:120,393,179...120,396,331
|
|
G |
Aplnr |
apelin receptor |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of APLNR mRNA |
CTD |
PMID:33367866 |
|
NCBI chr 3:70,217,407...70,221,052
Ensembl chr 3:70,217,385...70,221,050
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of ASNS mRNA |
CTD |
PMID:33367866 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of ATF4 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
2-ethylhexyldiphenylphosphate results in increased expression of BAX mRNA |
CTD |
PMID:30981936 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
C3ar1 |
complement C3a receptor 1 |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of C3AR1 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr 4:156,074,747...156,084,680
Ensembl chr 4:156,075,389...156,084,701
|
|
G |
Cdh5 |
cadherin 5 |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of CDH5 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
2-ethylhexyldiphenylphosphate results in increased expression of CDKN1A mRNA |
CTD |
PMID:30981936 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Ces1d |
carboxylesterase 1D |
decreases activity |
ISO |
2-ethylhexyldiphenylphosphate results in decreased activity of CES1 protein |
CTD |
PMID:31268531 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Cmtm7 |
CKLF-like MARVEL transmembrane domain containing 7 |
decreases expression |
ISO |
2-ethylhexyldiphenylphosphate results in decreased expression of CMTM7 mRNA |
CTD |
PMID:33969458 |
|
NCBI chr 8:114,448,037...114,474,958
Ensembl chr 8:114,448,042...114,474,621
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of COL10A1 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494
|
|
G |
Col13a1 |
collagen type XIII alpha 1 chain |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of COL13A1 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr20:29,783,965...29,924,116
Ensembl chr20:29,783,965...29,924,032
|
|
G |
Col24a1 |
collagen type XXIV alpha 1 chain |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of COL24A1 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr 2:234,212,256...234,469,445
Ensembl chr 2:234,212,324...234,469,441
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of CSF1R mRNA |
CTD |
PMID:33367866 |
|
NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415
|
|
G |
Cth |
cystathionine gamma-lyase |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of CTH mRNA |
CTD |
PMID:33367866 |
|
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of DDIT3 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression |
ISO |
2-ethylhexyldiphenylphosphate results in increased expression of FABP4 mRNA |
CTD |
PMID:31812418 |
|
NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
2-ethylhexyldiphenylphosphate results in increased expression of FASN mRNA |
CTD |
PMID:31812418 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of FGF21 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr 1:96,083,495...96,084,738
Ensembl chr 1:96,083,441...96,090,454
|
|
G |
Flcn |
folliculin |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of FLCN mRNA |
CTD |
PMID:33367866 |
|
NCBI chr10:44,588,621...44,607,808
Ensembl chr10:44,588,624...44,607,769
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
increases expression |
ISO |
2-ethylhexyldiphenylphosphate results in increased expression of GADD45B mRNA |
CTD |
PMID:30981936 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gdf15 |
growth differentiation factor 15 |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of GDF15 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr16:18,805,312...18,807,893
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
increases expression multiple interactions |
ISO |
2-ethylhexyldiphenylphosphate results in increased expression of HSD3B1 mRNA PPARG protein affects the reaction [2-ethylhexyldiphenylphosphate results in increased expression of HSD3B1 mRNA] |
CTD |
PMID:28282128 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Lpl |
lipoprotein lipase |
increases expression |
ISO |
2-ethylhexyldiphenylphosphate results in increased expression of LPL mRNA |
CTD |
PMID:31812418 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Mbp |
myelin basic protein |
decreases expression |
ISO |
2-ethylhexyldiphenylphosphate results in decreased expression of MBP mRNA |
CTD |
PMID:33969458 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression |
ISO |
2-ethylhexyldiphenylphosphate results in increased expression of MDM2 mRNA |
CTD |
PMID:30981936 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Muc1 |
mucin 1, cell surface associated |
increases expression |
ISO |
2-ethylhexyldiphenylphosphate results in increased expression of MUC1 mRNA |
CTD |
PMID:28282128 |
|
NCBI chr 2:174,635,559...174,640,738
Ensembl chr 2:174,635,995...174,640,733
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
multiple interactions |
ISO |
2-ethylhexyldiphenylphosphate inhibits the reaction [T0901317 results in increased activity of NR1H2 protein]; [Dust results in increased abundance of 2-ethylhexyldiphenylphosphate] inhibits the reaction [T0901317 results in increased activity of NR1H2 protein] |
CTD |
PMID:31724879 |
|
NCBI chr 1:95,041,967...95,047,377
Ensembl chr 1:95,041,967...95,047,377
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
2-ethylhexyldiphenylphosphate inhibits the reaction [T0901317 results in increased activity of NR1H3 protein]; [Dust results in increased abundance of 2-ethylhexyldiphenylphosphate] inhibits the reaction [T0901317 results in increased activity of NR1H3 protein] |
CTD |
PMID:31724879 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Pappa1 |
pappalysin 1 |
decreases expression |
ISO |
2-ethylhexyldiphenylphosphate results in decreased expression of PAPPA mRNA |
CTD |
PMID:28282128 |
|
NCBI chr 5:78,497,660...78,735,873
Ensembl chr 5:78,498,300...78,730,666
|
|
G |
Pck2 |
phosphoenolpyruvate carboxykinase 2 (mitochondrial) |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of PCK2 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr15:29,027,891...29,036,729
Ensembl chr15:29,027,894...29,037,283
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases activity |
ISO |
2-ethylhexyldiphenylphosphate binds to and results in increased activity of PPARG protein PPARG protein affects the reaction [2-ethylhexyldiphenylphosphate results in increased expression of HSD3B1 mRNA] 2-ethylhexyldiphenylphosphate results in increased activity of PPARG protein |
CTD |
PMID:28282128 PMID:31812418 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptprb |
protein tyrosine phosphatase, receptor type, B |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of PTPRB mRNA |
CTD |
PMID:33367866 |
|
NCBI chr 7:51,953,375...52,034,751
Ensembl chr 7:51,930,015...52,034,748
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of RUNX2 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Runx3 |
RUNX family transcription factor 3 |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of RUNX3 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr 5:147,393,926...147,419,161
Ensembl chr 5:147,360,994...147,419,156
|
|
G |
Smpd3 |
sphingomyelin phosphodiesterase 3 |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of SMPD3 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr19:34,162,337...34,245,786
Ensembl chr19:34,162,341...34,245,749
|
|
G |
Sp7 |
Sp7 transcription factor |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of SP7 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
2-ethylhexyldiphenylphosphate results in increased expression of TP53 mRNA |
CTD |
PMID:30981936 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of TRIB3 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression |
ISO |
Paraoxon results in decreased expression of ABCA1 protein |
CTD |
PMID:25250848 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Acbd5 |
acyl-CoA binding domain containing 5 |
increases expression |
ISO |
Paraoxon results in increased expression of ACBD5 mRNA |
CTD |
PMID:24413757 |
|
NCBI chr17:85,206,178...85,248,909
Ensembl chr17:85,206,303...85,248,215
|
|
G |
Ache |
acetylcholinesterase |
increases phosphorylation decreases activity multiple interactions increases activity increases acylation decreases expression increases expression |
ISO EXP |
Paraoxon results in increased phosphorylation of ACHE protein Paraoxon results in decreased activity of ACHE protein; Paraoxon results in decreased activity of ACHE protein mutant form 1,4-bis(2-hydroxyiminomethylpyridinium)butane inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 1,4-bis(4-hydroxyiminomethylpyridinium)butane dibromide inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 1-(4-hydroxyiminomethylpyridinium)-3-(carbamoylpyridinium) propane dibromide inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 1-(4-hydroxyiminomethylpyridinium)-4-(4-carbamoylpyridinium)butane inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; [Atropine co-treated with Obidoxime Chloride] inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; [Paraoxon co-treated with pralidoxime co-treated with Atropine] results in decreased activity of ACHE protein; asoxime chloride inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; N,N'-monomethylenebis(pyridiniumaldoxime) inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Obidoxime Chloride inhibits the reaction [[Paraoxon co-treated with pralidoxime co-treated with Atropine] results in decreased activity of ACHE protein]; Obidoxime Chloride inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; pralidoxime inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Ranitidine affects the reaction [Paraoxon results in decreased activity of ACHE protein]; Trimedoxime inhibits the reaction [Paraoxon results in decreased activity of ACHE protein] Paraoxon results in increased activity of ACHE protein Paraoxon results in increased acylation of ACHE protein Paraoxon results in decreased expression of ACHE mRNA ACHE protein inhibits the reaction [Paraoxon results in decreased expression of MCL1 polyA tail]; ACHE protein inhibits the reaction [Paraoxon results in increased abundance of Corticosterone]; Atropine promotes the reaction [Paraoxon results in increased phosphorylation of ACHE protein]; BCHE protein inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; coumarin inhibits the reaction [Paraoxon results in increased phosphorylation of ACHE protein]; Gallamine Triethiodide promotes the reaction [Paraoxon results in increased phosphorylation of ACHE protein]; HLo 7 inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Obidoxime Chloride inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Paraoxon results in increased phosphorylation of and results in decreased activity of ACHE protein; Propidium promotes the reaction [Paraoxon results in increased phosphorylation of ACHE protein]; Tubocurarine promotes the reaction [Paraoxon results in increased phosphorylation of ACHE protein] 1,3-bis(2-hydroxyiminomethylpyridinium)propane inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 1,4-bis(2-hydroxyiminomethylpyridinium)butane inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 1,4-bis(4-hydroxyiminomethylpyridinium)butane dibromide inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 1-((4-(aminocarbonyl)pyridinio)trimethylene)-2-((hydroxyimino)methyl)pyridinium inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 1-(4-carbamoylpyridinium)-4-(4-hydroxyiminomethylpyridinium)but-2-ene inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 1-(4-hydroxyiminomethylpyridinium)-3-(carbamoylpyridinium) propane dibromide inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 1-(4-hydroxyiminomethylpyridinium)-3-pyridiniumpropane inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 1-(4-hydroxyiminomethylpyridinium)-4-(4-carbamoylpyridinium)butane inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 4-(aminocarbonyl)-1-(3-(4-((E)-(hydroxyimino)methyl)pyridinium-1-yl)propyl)pyridinium dibromide inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 4-amino-2-((diethylamino)methyl)phenol analog inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; [alpha-Tocopherol co-treated with Paraoxon] results in decreased activity of ACHE protein; [Paraoxon co-treated with Dichlorvos] results in decreased activity of ACHE protein; [Polyethylene Glycols binds to PON1 protein] inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Amodiaquine analog inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Amodiaquine inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; asoxime chloride affects the reaction [Paraoxon results in decreased activity of ACHE protein]; asoxime chloride inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Atropine inhibits the reaction [Paraoxon results in increased expression of ACHE protein]; BCHE protein inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Cholinesterase Reactivators inhibits the reaction [Paraoxon binds to and results in decreased activity of ACHE protein]; diacetylmonoxime inhibits the reaction [Paraoxon binds to and results in decreased activity of ACHE protein]; Fullerenes analog inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Glucosides inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; HLo 7 inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; HS 3 inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; isonitrosoacetone inhibits the reaction [Paraoxon binds to and results in decreased activity of ACHE protein]; isonitrosoacetone inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; K075 compound inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; K117 compound inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; K127 compound inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; methamidophos promotes the reaction [Paraoxon results in decreased activity of ACHE protein]; Metoclopramide inhibits the reaction [Paraoxon binds to and results in decreased activity of ACHE protein]; Metoclopramide inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; N,N'-monomethylenebis(pyridiniumaldoxime) inhibits the reaction [Paraoxon binds to and results in decreased activity of ACHE protein]; N,N'-monomethylenebis(pyridiniumaldoxime) inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Obidoxime Chloride inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Paraoxon binds to and results in decreased activity of ACHE protein; Paraoxon promotes the reaction [methamidophos results in decreased activity of ACHE protein]; Paraoxon results in decreased expression of and results in decreased activity of ACHE protein; PON1 protein inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; pralidoxime inhibits the reaction [Paraoxon binds to and results in decreased activity of ACHE protein]; pralidoxime inhibits the reaction [Paraoxon results in decreased activity of ACHE protein mutant form]; pralidoxime inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; pyridine-2-aldoxime analog inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; pyridine-4-aldoxime analog inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; pyridine-4-aldoxime inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; pyridoxaloxime analog inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Ranitidine inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; RS194B analog inhibits the reaction [Paraoxon binds to and results in decreased activity of ACHE protein]; RS194B inhibits the reaction [Paraoxon binds to and results in decreased activity of ACHE protein]; RS41A inhibits the reaction [Paraoxon binds to and results in decreased activity of ACHE protein]; Tiapamil Hydrochloride inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Trimedoxime inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; trimethylene-bis(4-hydroxyiminomethylpyridinium) inhibits the reaction [Paraoxon results in decreased activity of ACHE protein] |
CTD |
PMID:1609424 PMID:4859365 PMID:8134223 PMID:8783813 PMID:9268605 PMID:9515941 PMID:10421444 PMID:12518340 PMID:12629810 PMID:12974645 PMID:14635269 PMID:15669026 PMID:15669039 PMID:15876422 PMID:16193528 PMID:16193529 PMID:16766477 PMID:16978018 PMID:17005312 PMID:17370251 PMID:18617161 PMID:19105816 PMID:19371630 PMID:20144593 PMID:20227398 PMID:20382137 PMID:20385200 PMID:20412789 PMID:20888407 PMID:20971170 PMID:21673941 PMID:21787676 PMID:21930118 PMID:22093924 PMID:22209767 PMID:22230262 PMID:22414384 PMID:22975155 PMID:23178380 PMID:23220589 PMID:24881594 PMID:25447325 PMID:26210933 PMID:26751814 PMID:26965078 PMID:27132127 PMID:27693733 PMID:28174098 PMID:28603072 PMID:29614332 PMID:30292885 PMID:30312685 PMID:30978295 PMID:33497710 PMID:33720374 PMID:34506764 More...
|
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Actb |
actin, beta |
increases expression |
ISO |
Paraoxon results in increased expression of ACTB protein |
CTD |
PMID:20931991 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases expression |
ISO |
Paraoxon results in increased expression of AHR mRNA |
CTD |
PMID:18519978 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akap12 |
A-kinase anchoring protein 12 |
decreases expression |
ISO |
Paraoxon results in decreased expression of AKAP12 mRNA |
CTD |
PMID:24413757 |
|
NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886
|
|
G |
Alb |
albumin |
affects binding increases hydrolysis multiple interactions decreases response to substance |
ISO |
Paraoxon binds to ALB protein ALB protein results in increased hydrolysis of Paraoxon ALB protein results in decreased susceptibility to [Paraoxon results in decreased activity of BCHE protein] ALB protein results in decreased susceptibility to Paraoxon |
CTD |
PMID:15525694 PMID:20211614 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Amot |
angiomotin |
decreases expression |
ISO |
Paraoxon results in decreased expression of AMOT mRNA |
CTD |
PMID:27117976 |
|
NCBI chr X:108,982,399...109,041,265
Ensembl chr X:108,984,022...109,041,272
|
|
G |
Apeh |
acylaminoacyl-peptide hydrolase |
affects binding |
ISO |
Paraoxon binds to APEH protein |
CTD |
PMID:31872761 |
|
NCBI chr 8:108,773,791...108,782,903
Ensembl chr 8:108,773,794...108,782,933
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
increases expression |
ISO |
Paraoxon results in increased expression of ARHGDIA protein |
CTD |
PMID:20931991 |
|
NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023
|
|
G |
Atp5f1b |
ATP synthase F1 subunit beta |
increases expression |
ISO |
Paraoxon results in increased expression of ATP5F1B protein |
CTD |
PMID:20931991 |
|
NCBI chr 7:515,454...521,858
Ensembl chr 7:515,460...567,273
|
|
G |
Axin2 |
axin 2 |
decreases expression |
ISO |
Paraoxon results in decreased expression of AXIN2 mRNA |
CTD |
PMID:24413757 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane analog inhibits the reaction [Paraoxon results in increased expression of and affects the localization of BAX protein]; Paraoxon results in increased expression of and affects the localization of BAX protein Paraoxon results in increased expression of BAX mRNA; Paraoxon results in increased expression of BAX protein |
CTD |
PMID:12831782 PMID:28603072 PMID:31493121 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions decreases response to substance decreases activity affects binding |
ISO EXP |
ALB protein results in decreased susceptibility to [Paraoxon results in decreased activity of BCHE protein]; Amodiaquine inhibits the reaction [Paraoxon results in decreased activity of BCHE protein]; asoxime chloride inhibits the reaction [Paraoxon results in decreased activity of BCHE protein]; BCHE protein inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; BCHE protein inhibits the reaction [Paraoxon results in decreased activity of BCHE protein]; Glucosides inhibits the reaction [Paraoxon results in decreased activity of BCHE protein]; Metoclopramide inhibits the reaction [Paraoxon binds to and results in decreased activity of BCHE protein]; Obidoxime Chloride inhibits the reaction [Paraoxon results in decreased activity of BCHE protein]; Paraoxon binds to and results in decreased activity of BCHE protein; pralidoxime inhibits the reaction [Paraoxon results in decreased activity of BCHE protein]; pyridine-4-aldoxime inhibits the reaction [Paraoxon results in decreased activity of BCHE protein]; pyridoxaloxime analog inhibits the reaction [Paraoxon results in decreased activity of BCHE protein]; Ranitidine inhibits the reaction [Paraoxon results in decreased activity of BCHE protein]; Tiapamil Hydrochloride inhibits the reaction [Paraoxon results in decreased activity of BCHE protein]; Trimedoxime inhibits the reaction [Paraoxon results in decreased activity of BCHE protein] BCHE protein results in decreased susceptibility to Paraoxon Paraoxon binds to BCHE protein; Paraoxon binds to BCHE protein modified form Paraoxon results in decreased activity of BCHE mRNA; Paraoxon results in decreased activity of BCHE protein |
CTD |
PMID:4631366 PMID:12518340 PMID:12629810 PMID:15669026 PMID:16193528 PMID:16213467 PMID:18514178 PMID:18617161 PMID:19272400 PMID:20206154 PMID:20211614 PMID:20227398 PMID:21673941 PMID:22209767 PMID:23178380 PMID:24912784 PMID:27108687 PMID:27693733 PMID:29614332 PMID:31201777 PMID:33497710 PMID:33592259 More...
|
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO EXP |
Paraoxon results in decreased expression of BCL2 mRNA Paraoxon results in decreased expression of BCL2 mRNA; Paraoxon results in decreased expression of BCL2 protein |
CTD |
PMID:27117976 PMID:28603072 PMID:31493121 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Casp12 |
caspase 12 |
multiple interactions increases expression |
ISO |
Egtazic Acid inhibits the reaction [Paraoxon results in increased expression of CASP12 protein]; Heparin inhibits the reaction [Paraoxon results in increased expression of CASP12 protein]; Procaine inhibits the reaction [Paraoxon results in increased expression of CASP12 protein] |
CTD |
PMID:20079824 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp3 |
caspase 3 |
increases activity increases expression multiple interactions |
ISO EXP |
Paraoxon results in increased activity of CASP3 protein Paraoxon results in increased expression of CASP3 mRNA; Paraoxon results in increased expression of CASP3 protein Cyclosporine inhibits the reaction [Paraoxon results in increased activity of CASP3 protein] benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Paraoxon results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane analog inhibits the reaction [Paraoxon results in increased cleavage of and results in increased activity of CASP3 protein]; Metoclopramide inhibits the reaction [Paraoxon results in increased activity of and results in increased cleavage of CASP3 protein]; Paraoxon results in increased activity of and results in increased cleavage of CASP3 protein; Paraoxon results in increased cleavage of and results in increased activity of CASP3 protein Ro 31-8220 inhibits the reaction [Paraoxon results in increased activity of CASP3 protein] |
CTD |
PMID:11032765 PMID:12831782 PMID:17561261 PMID:29027213 PMID:31493121 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Paraoxon results in increased cleavage of and results in increased activity of CASP8 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Paraoxon results in increased cleavage of and results in increased activity of CASP8 protein]; benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane analog inhibits the reaction [Paraoxon results in increased cleavage of and results in increased activity of CASP8 protein]; Paraoxon results in increased cleavage of and results in increased activity of CASP8 protein |
CTD |
PMID:12831782 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Paraoxon results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane analog inhibits the reaction [Paraoxon results in increased cleavage of and results in increased activity of CASP9 protein]; Paraoxon results in increased cleavage of and results in increased activity of CASP9 protein |
CTD |
PMID:12831782 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccdc177 |
coiled-coil domain containing 177 |
decreases expression |
ISO |
Paraoxon results in decreased expression of CCDC177 mRNA |
CTD |
PMID:24413757 |
|
NCBI chr 6:100,400,010...100,411,221
Ensembl chr 6:100,404,413...100,412,850
|
|
G |
Ccr6 |
C-C motif chemokine receptor 6 |
increases expression |
ISO |
Paraoxon results in increased expression of CCR6 mRNA |
CTD |
PMID:24413757 |
|
NCBI chr 1:52,474,477...52,508,301
Ensembl chr 1:52,474,168...52,498,603
|
|
G |
Ces1d |
carboxylesterase 1D |
decreases activity affects binding |
ISO |
Paraoxon results in decreased activity of CES1 protein Paraoxon binds to CES1 protein |
CTD |
PMID:11950785 PMID:25250848 PMID:31872761 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2h |
carboxylesterase 2H |
decreases activity |
ISO |
Paraoxon results in decreased activity of CES2 protein |
CTD |
PMID:11950785 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Ces3a |
carboxylesterase 3a |
decreases activity |
ISO |
Paraoxon results in decreased activity of CES3 protein |
CTD |
PMID:11950785 |
|
NCBI chr19:32,992,386...33,000,562
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
decreases expression |
ISO |
Paraoxon results in decreased expression of CHRM1 mRNA |
CTD |
PMID:21787676 |
|
NCBI chr 1:205,567,046...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
decreases expression |
ISO |
Paraoxon results in decreased expression of CHRM2 mRNA |
CTD |
PMID:21787676 |
|
NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
|
|
G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
decreases expression |
ISO |
Paraoxon results in decreased expression of CHRM3 mRNA |
CTD |
PMID:21787676 |
|
NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions decreases expression |
EXP |
Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 mRNA]]; Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 protein]]; Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 mRNA]; Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 protein] Paraoxon results in decreased expression of CHRNA4 mRNA; Paraoxon results in decreased expression of CHRNA4 protein |
CTD |
PMID:21791372 |
|
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions decreases expression |
EXP |
Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNB2 mRNA]]; Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNB2 protein]]; Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNB2 mRNA]; Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNB2 protein] Paraoxon results in decreased expression of CHRNB2 mRNA; Paraoxon results in decreased expression of CHRNB2 protein |
CTD |
PMID:21791372 |
|
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Clk1 |
CDC-like kinase 1 |
increases expression |
ISO |
Paraoxon results in increased expression of CLK1 mRNA |
CTD |
PMID:22093924 |
|
NCBI chr 9:59,947,774...59,959,002
Ensembl chr 9:59,947,764...59,957,000
|
|
G |
Clk3 |
CDC-like kinase 3 |
increases expression |
ISO |
Paraoxon results in increased expression of CLK3 mRNA |
CTD |
PMID:22093924 |
|
NCBI chr 8:58,152,155...58,167,196
Ensembl chr 8:58,152,155...58,168,181
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions decreases activity |
ISO |
Paraoxon inhibits the reaction [CP 55244 binds to CNR1 protein] Paraoxon results in decreased activity of CNR1 protein |
CTD |
PMID:12243867 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
Paraoxon inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA] |
CTD |
PMID:24555085 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Eno1 |
enolase 1 |
decreases expression |
ISO |
Paraoxon results in decreased expression of ENO1 protein |
CTD |
PMID:20931991 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases activity |
ISO |
Paraoxon results in decreased activity of ESR1 protein |
CTD |
PMID:22562034 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
F2 |
coagulation factor II |
increases activity multiple interactions |
ISO |
Paraoxon results in increased activity of F2 protein [Paraoxon co-treated with Atropine co-treated with Obidoxime Chloride] results in decreased expression of F2 mRNA; [Paraoxon co-treated with Atropine co-treated with Obidoxime Chloride] results in increased activity of F2 protein |
CTD |
PMID:30515700 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
multiple interactions |
ISO |
[Paraoxon co-treated with Atropine co-treated with Obidoxime Chloride] results in increased expression of F2R protein |
CTD |
PMID:30515700 |
|
NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
|
|
G |
Faah |
fatty acid amide hydrolase |
decreases activity |
EXP |
Paraoxon results in decreased activity of FAAH protein |
CTD |
PMID:25447325 |
|
NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
decreases expression |
ISO |
Paraoxon results in decreased expression of FGFR1 mRNA |
CTD |
PMID:24413757 |
|
NCBI chr16:66,492,445...66,546,731
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
Atropine inhibits the reaction [Paraoxon results in increased expression of FOS mRNA] |
CTD |
PMID:21787676 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gap43 |
growth associated protein 43 |
decreases expression |
ISO |
Paraoxon results in decreased expression of GAP43 protein |
CTD |
PMID:27939611 |
|
NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
Paraoxon results in increased expression of GCLM mRNA |
CTD |
PMID:24413757 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gss |
glutathione synthetase |
increases expression |
ISO |
Paraoxon results in increased expression of GSS |
CTD |
PMID:24486155 |
|
NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:144,047,850...144,078,198
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
increases expression |
ISO |
Paraoxon results in increased expression of GSTM2 |
CTD |
PMID:24486155 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gstt2 |
glutathione S-transferase, theta 2 |
increases expression |
ISO |
Paraoxon results in increased expression of GSTT2 |
CTD |
PMID:24486155 |
|
NCBI chr20:12,819,617...12,823,288
Ensembl chr20:12,819,170...12,823,288
|
|
G |
H2ac12 |
H2A clustered histone 12 |
decreases expression |
ISO |
Paraoxon results in decreased expression of H2AC12 protein |
CTD |
PMID:20931991 |
|
NCBI chr17:42,486,315...42,486,880
Ensembl chr17:42,486,415...42,486,941
|
|
G |
H2ac4 |
H2A clustered histone 4 |
decreases expression |
ISO |
Paraoxon results in decreased expression of H2AC4 mRNA |
CTD |
PMID:24413757 |
|
NCBI chr17:42,799,953...42,800,345
Ensembl chr17:42,799,652...42,800,381
|
|
G |
Hnrnpc |
heterogeneous nuclear ribonucleoprotein C |
increases expression |
ISO |
Paraoxon results in increased expression of HNRNPC protein |
CTD |
PMID:20931991 |
|
NCBI chr15:24,779,593...24,809,213
Ensembl chr15:24,779,450...24,809,183
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
decreases expression |
ISO |
Paraoxon results in decreased expression of HSP90AA1 protein |
CTD |
PMID:20931991 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
decreases expression |
ISO |
Paraoxon results in decreased expression of HSP90AB1 protein |
CTD |
PMID:20931991 |
|
NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488
|
|
G |
Il2 |
interleukin 2 |
decreases response to substance |
ISO |
Paraoxon results in decreased susceptibility to IL2 protein |
CTD |
PMID:8349949 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il6 |
interleukin 6 |
decreases expression |
ISO |
Paraoxon results in decreased expression of IL6 mRNA |
CTD |
PMID:22093924 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ildr1 |
immunoglobulin-like domain containing receptor 1 |
increases expression |
ISO |
Paraoxon results in increased expression of ILDR1 mRNA |
CTD |
PMID:24413757 |
|
NCBI chr11:64,085,774...64,118,760
Ensembl chr11:64,008,566...64,118,760
|
|
G |
Ilf2 |
interleukin enhancer binding factor 2 |
increases expression |
ISO |
Paraoxon results in increased expression of ILF2 protein |
CTD |
PMID:20931991 |
|
NCBI chr 2:175,951,002...175,971,193
Ensembl chr 2:175,952,186...175,971,337
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
Paraoxon results in decreased expression of JUN mRNA |
CTD |
PMID:27117976 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kirrel2 |
kirre like nephrin family adhesion molecule 2 |
increases expression |
ISO |
Paraoxon results in increased expression of KIRREL2 mRNA |
CTD |
PMID:24413757 |
|
NCBI chr 1:85,708,793...85,718,670
Ensembl chr 1:85,708,793...85,718,670
|
|
G |
Lat2 |
linker for activation of T cells family, member 2 |
increases expression |
ISO |
Paraoxon results in increased expression of LAT2 mRNA |
CTD |
PMID:24413757 |
|
NCBI chr12:22,104,163...22,118,294
Ensembl chr12:22,104,219...22,118,288
|
|
G |
Lipa |
lipase A, lysosomal acid type |
decreases activity |
ISO |
Paraoxon results in decreased activity of LIPA protein |
CTD |
PMID:25250848 |
|
NCBI chr 1:232,024,351...232,167,329
Ensembl chr 1:232,024,356...232,057,633
|
|
G |
Lmnb2 |
lamin B2 |
increases expression |
ISO |
Paraoxon results in increased expression of LMNB2 protein |
CTD |
PMID:20931991 |
|
NCBI chr 7:8,792,628...8,808,665
Ensembl chr 7:8,789,314...8,808,665
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions decreases expression increases expression |
ISO |
ACHE protein inhibits the reaction [Paraoxon results in decreased expression of MCL1 polyA tail] Paraoxon results in increased expression of MCL1 protein alternative form |
CTD |
PMID:22093924 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
decreases activity |
ISO |
Paraoxon results in decreased activity of NCEH1 protein |
CTD |
PMID:16449251 PMID:16978018 |
|
NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:110,074,957...110,135,588
|
|
G |
Nefh |
neurofilament heavy chain |
decreases expression |
ISO |
Paraoxon results in decreased expression of NEFH protein |
CTD |
PMID:27939611 |
|
NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351
|
|
G |
Nes |
nestin |
increases expression |
ISO |
Paraoxon results in increased expression of NES mRNA |
CTD |
PMID:27117976 |
|
NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
[NR1I3 protein affects the metabolism of Parathion] which affects the chemical synthesis of Paraoxon |
CTD |
PMID:20573718 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Orm1 |
orosomucoid 1 |
increases expression |
EXP |
Paraoxon results in increased expression of ORM1 mRNA |
CTD |
PMID:17497759 |
|
NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
Paraoxon results in increased cleavage of PARP1 protein Metoclopramide inhibits the reaction [Paraoxon results in increased cleavage of PARP1 protein] |
CTD |
PMID:29027213 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Parp4 |
poly (ADP-ribose) polymerase family, member 4 |
increases expression |
ISO |
Paraoxon results in increased expression of PARP4 mRNA |
CTD |
PMID:24413757 |
|
NCBI chr15:30,690,503...30,792,868
Ensembl chr15:30,686,613...30,828,810
|
|
G |
Pcnx4 |
pecanex 4 |
increases expression |
ISO |
Paraoxon results in increased expression of PCNX4 mRNA |
CTD |
PMID:24413757 |
|
NCBI chr 6:91,125,063...91,170,423
Ensembl chr 6:91,125,063...91,170,439
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
increases expression |
ISO |
Paraoxon results in increased expression of PDGFA mRNA |
CTD |
PMID:30978295 |
|
NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497
|
|
G |
Phb1 |
prohibitin 1 |
decreases expression |
ISO |
Paraoxon results in decreased expression of PHB1 protein |
CTD |
PMID:20931991 |
|
NCBI chr10:80,605,268...80,618,043
Ensembl chr10:80,605,251...80,618,042
|
|
G |
Pnliprp2 |
pancreatic lipase related protein 2 |
decreases activity |
ISO EXP |
Paraoxon results in decreased activity of PNLIPRP2 protein |
CTD |
PMID:9822688 PMID:17401110 |
|
NCBI chr 1:257,897,766...257,916,434
Ensembl chr 1:257,897,766...257,916,434
|
|
G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
multiple interactions decreases activity |
ISO |
[Paraoxon co-treated with mipafox] results in decreased activity of PNPLA6 protein Paraoxon results in decreased activity of PNPLA6 protein |
CTD |
PMID:9268605 PMID:19620706 |
|
NCBI chr12:1,574,387...1,603,735
Ensembl chr12:1,560,363...1,603,734
|
|
G |
Pon1 |
paraoxonase 1 |
increases activity decreases response to substance multiple interactions increases hydrolysis affects metabolic processing increases metabolic processing affects response to substance affects hydrolysis |
ISO EXP |
Paraoxon results in increased activity of PON1 protein PON1 results in decreased susceptibility to Paraoxon [Alendronate results in decreased activity of PON1 protein] which results in decreased metabolism of Paraoxon; [Calcium results in increased activity of PON1 protein] which results in decreased susceptibility to Paraoxon; [Clodronic Acid results in decreased activity of PON1 protein] which results in decreased metabolism of Paraoxon; [Egtazic Acid results in decreased activity of PON1 protein] which results in increased susceptibility to Paraoxon; [Ibandronic Acid results in decreased activity of PON1 protein] which results in decreased metabolism of Paraoxon; [Pamidronate results in decreased activity of PON1 protein] which results in decreased metabolism of Paraoxon; [Risedronic Acid results in increased activity of PON1 protein] which results in increased metabolism of Paraoxon; Fluvastatin inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon] 2-hydroxyquinoline inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; 4-hydroxy-2-nonenal inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; [Ascorbic Acid co-treated with Copper Sulfate] inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; [Ascorbic Acid co-treated with ferrous sulfate] inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; [Calcium results in increased activity of PON1 protein] which results in decreased susceptibility to Paraoxon; [Egtazic Acid results in decreased activity of PON1 protein] which results in increased susceptibility to Paraoxon; [Polyethylene Glycols binds to PON1 protein] inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; [Polyethylene Glycols binds to PON1 protein] which results in increased hydrolysis of Paraoxon; Arachidonic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Calcium Chloride promotes the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Hydrogen Peroxide inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Linoleic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; lysophosphatidylglycerol inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; lysophosphatidylinositol inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Oleic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Oxygen promotes the reaction [PON1 protein affects the metabolism of Paraoxon]; palmitoleic acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; PON1 protein inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; PON1 protein polymorphism affects the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Pyruvaldehyde inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon] PON1 protein mutant form results in increased hydrolysis of Paraoxon; PON1 protein results in increased hydrolysis of Paraoxon PON1 protein mutant form results in decreased susceptibility to Paraoxon PON1 protein affects the metabolism of Paraoxon; PON1 protein polymorphism affects the metabolism of Paraoxon PON1 protein results in increased metabolism of Paraoxon PON1 gene polymorphism affects the susceptibility to Paraoxon PON1 3' UTR SNP affects the hydrolysis of Paraoxon; PON1 intron SNP affects the hydrolysis of Paraoxon; PON1 protein polymorphism affects the hydrolysis of Paraoxon |
CTD |
PMID:9313934 PMID:9746266 PMID:11022865 PMID:11304470 PMID:14668577 PMID:15375178 PMID:15924216 PMID:16052486 PMID:16055108 PMID:16079929 PMID:16175651 PMID:16331452 PMID:16391483 PMID:18519978 PMID:19071155 PMID:19446239 PMID:20176005 PMID:20839225 PMID:21382471 PMID:21629682 PMID:22414384 PMID:23159884 PMID:23223497 PMID:25867687 PMID:27132127 PMID:27256520 PMID:27387541 More...
|
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
increases expression |
ISO |
Paraoxon results in increased expression of PTK2B mRNA |
CTD |
PMID:24413757 |
|
NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282
|
|
G |
SET |
SET nuclear proto-oncogene |
increases expression |
ISO |
Paraoxon results in increased expression of SET mRNA |
CTD |
PMID:24413757 |
|
NCBI chr 3:13,334,564...13,345,598
Ensembl chr 3:13,335,041...13,363,567
|
|
G |
Slc1a1 |
solute carrier family 1 member 1 |
decreases expression |
EXP |
Paraoxon results in decreased expression of SLC1A1 mRNA; Paraoxon results in decreased expression of SLC1A1 protein |
CTD |
PMID:28603072 |
|
NCBI chr 1:226,549,932...226,631,925
Ensembl chr 1:226,549,842...226,630,402
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
increases expression affects expression |
EXP |
Paraoxon results in increased expression of SLC1A2 mRNA; Paraoxon results in increased expression of SLC1A2 protein Paraoxon affects the expression of SLC1A2 mRNA; Paraoxon affects the expression of SLC1A2 protein |
CTD |
PMID:27769869 PMID:28603072 |
|
NCBI chr 3:89,005,129...89,126,498
Ensembl chr 3:89,005,129...89,126,498
|
|
G |
Slc1a3 |
solute carrier family 1 member 3 |
increases expression affects expression |
EXP |
Paraoxon results in increased expression of SLC1A3 mRNA; Paraoxon results in increased expression of SLC1A3 protein Paraoxon affects the expression of SLC1A3 mRNA; Paraoxon affects the expression of SLC1A3 protein |
CTD |
PMID:27769869 PMID:28603072 |
|
NCBI chr 2:57,755,495...57,830,605
Ensembl chr 2:57,755,497...57,830,605
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression |
ISO |
Paraoxon results in increased expression of SOD2 |
CTD |
PMID:24486155 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Syn1 |
synapsin I |
decreases expression |
ISO |
Paraoxon results in decreased expression of SYN1 protein |
CTD |
PMID:27939611 |
|
NCBI chr X:1,172,208...1,227,400
Ensembl chr X:1,172,208...1,227,396
|
|
G |
Syp |
synaptophysin |
decreases expression |
ISO |
Paraoxon results in decreased expression of SYP protein |
CTD |
PMID:27939611 |
|
NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
Paraoxon results in increased expression of TGFB1 mRNA |
CTD |
PMID:30978295 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression increases expression |
ISO |
Paraoxon results in decreased expression of TNF mRNA Paraoxon results in increased expression of TNF mRNA |
CTD |
PMID:22093924 PMID:30978295 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions |
ISO |
Paraoxon results in increased expression of TRP53 protein benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane analog inhibits the reaction [Paraoxon results in increased expression of TRP53 protein] |
CTD |
PMID:12831782 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpm4 |
tropomyosin 4 |
increases expression |
ISO |
Paraoxon results in increased expression of TPM4 protein |
CTD |
PMID:20931991 |
|
NCBI chr16:17,684,415...17,698,456
Ensembl chr16:17,683,195...17,705,984
|
|
G |
Ttc16 |
tetratricopeptide repeat domain 16 |
increases expression |
ISO |
Paraoxon results in increased expression of TTC16 mRNA |
CTD |
PMID:24413757 |
|
NCBI chr 3:16,048,484...16,064,598
Ensembl chr 3:16,048,565...16,064,547
|
|
G |
Tufm |
Tu translation elongation factor, mitochondrial |
increases expression |
ISO |
Paraoxon results in increased expression of TUFM protein |
CTD |
PMID:20931991 |
|
NCBI chr 1:181,073,788...181,077,395
Ensembl chr 1:181,073,788...181,077,395
|
|
G |
Ube2z |
ubiquitin-conjugating enzyme E2Z |
decreases expression |
ISO |
Paraoxon results in decreased expression of UBE2Z mRNA |
CTD |
PMID:24413757 |
|
NCBI chr10:80,997,816...81,016,936
Ensembl chr10:80,997,817...81,016,936
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Paraoxon results in decreased expression of VEGFA mRNA |
CTD |
PMID:27117976 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Yap1 |
Yes1 associated transcriptional regulator |
decreases expression |
ISO |
Paraoxon results in decreased expression of YAP1 mRNA |
CTD |
PMID:24413757 |
|
NCBI chr 8:5,095,705...5,166,808
Ensembl chr 8:5,095,722...5,167,010
|
|
G |
Zfp36 |
zinc finger protein 36 |
increases expression |
ISO |
Paraoxon results in increased expression of ZFP36 mRNA |
CTD |
PMID:22093924 |
|
NCBI chr 1:83,669,084...83,671,564
Ensembl chr 1:83,669,084...83,671,564
|
|
G |
Zfyve19 |
zinc finger FYVE-type containing 19 |
increases expression |
ISO |
Paraoxon results in increased expression of ZFYVE19 protein |
CTD |
PMID:20931991 |
|
NCBI chr 3:106,195,779...106,203,969
Ensembl chr 3:106,195,899...106,203,969
|
|
|
G |
Aacs |
acetoacetyl-CoA synthetase |
increases expression |
EXP |
triphenyl phosphate results in increased expression of AACS mRNA |
CTD |
PMID:30589522 |
|
NCBI chr12:31,113,098...31,156,411
Ensembl chr12:31,113,098...31,160,954
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression |
ISO |
triphenyl phosphate results in decreased expression of ABCA1 mRNA |
CTD |
PMID:31724879 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
[tris(1,3-dichloro-2-propyl)phosphate co-treated with Tritolyl Phosphates co-treated with triphenyl phosphate] results in increased expression of ABCB11 mRNA |
CTD |
PMID:32360330 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ABCB1A mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ABCB4 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcb9 |
ATP binding cassette subfamily B member 9 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ABCB9 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr12:32,499,225...32,531,932
Ensembl chr12:32,499,225...32,531,931
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ABCC2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ABCC3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ABCC4 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcd2 |
ATP binding cassette subfamily D member 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ABCD2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 7:122,263,034...122,311,642
Ensembl chr 7:122,263,032...122,311,642
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
multiple interactions decreases expression |
ISO |
triphenyl phosphate inhibits the reaction [T0901317 results in increased expression of ABCG1 mRNA] triphenyl phosphate results in decreased expression of ABCG1 mRNA |
CTD |
PMID:31724879 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ABCG5 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ABCG8 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Abhd1 |
abhydrolase domain containing 1 |
affects expression |
EXP |
triphenyl phosphate affects the expression of ABHD1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:25,422,526...25,427,514
Ensembl chr 6:25,422,526...25,427,514
|
|
G |
Abhd5 |
abhydrolase domain containing 5, lysophosphatidic acid acyltransferase |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ABHD5 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:122,000,241...122,026,447
Ensembl chr 8:122,000,389...122,026,447
|
|
G |
Abi3bp |
ABI family member 3 binding protein |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ABI3BP mRNA |
CTD |
PMID:30589522 |
|
NCBI chr11:43,912,187...44,128,888
Ensembl chr11:43,913,043...44,128,929
|
|
G |
Ablim1 |
actin-binding LIM protein 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ABLIM1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:256,084,293...256,372,075
Ensembl chr 1:256,084,297...256,371,969
|
|
G |
Ablim3 |
actin binding LIM protein family, member 3 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ABLIM3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr18:55,256,135...55,376,629
Ensembl chr18:55,257,583...55,376,380
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ACACA mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acad9 |
acyl-CoA dehydrogenase family, member 9 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ACAD9 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:118,943,170...118,966,150
Ensembl chr 2:118,943,174...118,966,547
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
affects expression |
EXP |
triphenyl phosphate affects the expression of ACAT2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821
|
|
G |
Acer2 |
alkaline ceramidase 2 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ACER2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:101,391,830...101,442,615
Ensembl chr 5:101,391,885...101,442,614
|
|
G |
Acly |
ATP citrate lyase |
affects expression |
EXP |
triphenyl phosphate affects the expression of ACLY mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Aco1 |
aconitase 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ACO1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391
|
|
G |
Acot4 |
acyl-CoA thioesterase 4 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ACOT4 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:103,668,699...103,674,037
Ensembl chr 6:103,668,753...103,673,917
|
|
G |
Acox3 |
acyl-CoA oxidase 3, pristanoyl |
affects expression |
EXP |
triphenyl phosphate affects the expression of ACOX3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr14:75,133,986...75,176,767
Ensembl chr14:75,094,676...75,176,205
|
|
G |
Acsl5 |
acyl-CoA synthetase long-chain family member 5 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ACSL5 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607
|
|
G |
Acsm2 |
acyl-CoA synthetase medium-chain family member 2 |
affects expression |
EXP |
triphenyl phosphate affects the expression of ACSM2A mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:173,916,368...173,955,116
Ensembl chr 1:173,916,368...173,955,116
|
|
G |
Acsm3 |
acyl-CoA synthetase medium-chain family member 3 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ACSM3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:174,133,260...174,159,966
Ensembl chr 1:174,133,288...174,160,184
|
|
G |
Acsm5 |
acyl-CoA synthetase medium-chain family member 5 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ACSM5 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:173,870,873...173,896,838
Ensembl chr 1:173,863,041...173,898,588
|
|
G |
Acss2 |
acyl-CoA synthetase short-chain family member 2 |
affects expression |
EXP |
triphenyl phosphate affects the expression of ACSS2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675
|
|
G |
Actg1 |
actin, gamma 1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ACTG1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:105,619,738...105,622,587
Ensembl chr10:105,619,737...105,624,232
|
|
G |
Acy3 |
aminoacylase 3 |
affects expression |
EXP |
triphenyl phosphate affects the expression of ACY3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:201,279,751...201,285,803
Ensembl chr 1:201,279,851...201,283,175
|
|
G |
Acyp1 |
acylphosphatase 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ACYP1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:104,919,162...104,932,348
Ensembl chr 6:104,919,162...104,932,387
|
|
G |
Acyp2 |
acylphosphatase 2 |
affects expression |
EXP |
triphenyl phosphate affects the expression of ACYP2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr14:104,201,894...104,371,415
Ensembl chr14:104,201,895...104,371,386
|
|
G |
Adam11 |
ADAM metallopeptidase domain 11 |
affects expression |
EXP |
triphenyl phosphate affects the expression of ADAM11 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:87,724,115...87,742,773
Ensembl chr10:87,724,234...87,741,562
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ADAMTS1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adamts7 |
ADAM metallopeptidase with thrombospondin type 1 motif, 7 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ADAMTS7 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:90,704,727...90,744,331
Ensembl chr 8:90,704,727...90,744,328
|
|
G |
Adamts9 |
ADAM metallopeptidase with thrombospondin type 1 motif, 9 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ADAMTS9 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:125,290,633...125,462,988
Ensembl chr 4:125,291,490...125,462,929
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ADGRE1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000
|
|
G |
Adgrg2 |
adhesion G protein-coupled receptor G2 |
affects expression |
EXP |
triphenyl phosphate affects the expression of ADGRG2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr X:34,297,402...34,422,590
Ensembl chr X:34,297,402...34,422,609
|
|
G |
Adh1 |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
affects expression |
EXP |
triphenyl phosphate affects the expression of ADH1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Adh4 |
alcohol dehydrogenase 4 (class II), pi polypeptide |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ADH4 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591
|
|
G |
Adh7 |
alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide |
affects expression |
EXP |
triphenyl phosphate affects the expression of ADH7 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:226,748,724...226,763,183
Ensembl chr 2:226,741,788...226,763,182
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression multiple interactions |
ISO |
triphenyl phosphate results in increased expression of ADIPOQ mRNA [triphenyl phosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA; [triphenyl phosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased secretion of ADIPOQ protein |
CTD |
PMID:28934090 PMID:34323617 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adm |
adrenomedullin |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of ADM mRNA |
CTD |
PMID:33367866 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Adm2 |
adrenomedullin 2 |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of ADM2 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr 7:120,393,219...120,394,965
Ensembl chr 7:120,393,179...120,396,331
|
|
G |
Adra2b |
adrenoceptor alpha 2B |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ADRA2B mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:114,585,174...114,589,220
Ensembl chr 3:114,585,169...114,589,355
|
|
G |
Adss1 |
adenylosuccinate synthase 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ADSSL1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:131,679,795...131,702,012
Ensembl chr 6:131,679,701...131,701,998
|
|
G |
Afmid |
arylformamidase |
affects expression |
EXP |
triphenyl phosphate affects the expression of AFMID mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:103,046,129...103,061,718
Ensembl chr10:103,046,180...103,061,718
|
|
G |
Agrp |
agouti related neuropeptide |
multiple interactions |
ISO |
[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of AGRP mRNA; [tris(1,3-dichloro-2-propyl)phosphate co-treated with Tritolyl Phosphates co-treated with triphenyl phosphate] results in increased expression of AGRP mRNA |
CTD |
PMID:29112739 PMID:32360330 |
|
NCBI chr19:33,447,992...33,523,068
Ensembl chr19:33,447,992...33,449,584
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of AGTR1A mRNA |
CTD |
PMID:30589522 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Agxt |
alanine--glyoxylate and serine--pyruvate aminotransferase |
affects expression |
EXP |
triphenyl phosphate affects the expression of AGXT mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 9:93,675,384...93,685,337
Ensembl chr 9:93,675,384...93,685,336
|
|
G |
Ak3 |
adenylate kinase 3 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of AK3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:226,737,472...226,764,647
Ensembl chr 1:226,739,318...226,764,625
|
|
G |
Ak4 |
adenylate kinase 4 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of AK4 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:116,039,222...116,099,064
Ensembl chr 5:116,039,616...116,098,618
|
|
G |
Akap13 |
A-kinase anchoring protein 13 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of AKAP13 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:129,313,183...129,619,647
Ensembl chr 1:129,314,402...129,619,646
|
|
G |
Akap2 |
A-kinase anchoring protein 2 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of AKAP2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:72,536,986...72,648,524
Ensembl chr 5:72,181,718...72,648,524
|
|
G |
Akr1b7 |
aldo-keto reductase family 1, member B7 |
affects expression |
EXP |
triphenyl phosphate affects the expression of AKR1B7 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:63,053,560...63,100,934
Ensembl chr 4:63,076,800...63,089,502
|
|
G |
Akr1b8 |
aldo-keto reductase family 1, member B8 |
affects expression |
EXP |
triphenyl phosphate affects the expression of AKR1B8 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:62,997,241...63,009,815
Ensembl chr 4:62,997,161...63,010,097
|
|
G |
Akr7a2 |
aldo-keto reductase family 7, member A2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of AKR7A2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
|
|
G |
Akr7a3 |
aldo-keto reductase family 7 member A3 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of AKR7A3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ALAS1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:106,876,514...106,889,852
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Alas2 |
5'-aminolevulinate synthase 2 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ALAS2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr X:19,463,146...19,486,526
Ensembl chr X:19,463,171...19,486,519
|
|
G |
Alb |
albumin |
decreases secretion |
EXP |
triphenyl phosphate results in decreased secretion of ALB protein |
CTD |
PMID:30589522 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alcam |
activated leukocyte cell adhesion molecule |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ALCAM mRNA |
CTD |
PMID:30589522 |
|
NCBI chr11:48,336,123...48,536,296
Ensembl chr11:48,336,169...48,537,954
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
affects expression |
EXP |
triphenyl phosphate affects the expression of ALDH1A3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436
|
|
G |
Amigo2 |
adhesion molecule with Ig like domain 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of AMIGO2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 7:128,391,493...128,394,589
Ensembl chr 7:128,390,412...128,394,695
|
|
G |
Amz1 |
archaelysin family metallopeptidase 1 |
decreases expression |
ISO |
triphenyl phosphate results in decreased expression of AMZ1 mRNA |
CTD |
PMID:28934090 |
|
NCBI chr12:13,886,533...13,924,275
Ensembl chr12:13,891,123...13,909,783
|
|
G |
Angptl4 |
angiopoietin-like 4 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ANGPTL4 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
|
|
G |
Ankrd33b |
ankyrin repeat domain 33B |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ANKRD33B mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:82,277,604...82,359,420
Ensembl chr 2:82,283,108...82,358,872
|
|
G |
Ankrd46 |
ankyrin repeat domain 46 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ANKRD46 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 7:67,647,202...67,668,180
Ensembl chr 7:67,647,204...67,668,132
|
|
G |
Anxa1 |
annexin A1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ANXA1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Anxa3 |
annexin A3 |
affects expression |
EXP |
triphenyl phosphate affects the expression of ANXA3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617
|
|
G |
Anxa7 |
annexin A7 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ANXA7 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr15:3,821,798...3,849,659
Ensembl chr15:3,821,845...3,849,385
|
|
G |
Aox1 |
aldehyde oxidase 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of AOX1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770
|
|
G |
Ap3m1 |
adaptor related protein complex 3 subunit mu 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of AP3M1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr15:3,246,616...3,264,846
Ensembl chr15:3,246,926...3,264,844
|
|
G |
Aplf |
aprataxin and PNKP like factor |
increases expression |
EXP |
triphenyl phosphate results in increased expression of APLF mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:120,070,471...120,122,656
Ensembl chr 4:120,070,471...120,122,633
|
|
G |
Aplnr |
apelin receptor |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of APLNR mRNA |
CTD |
PMID:33367866 |
|
NCBI chr 3:70,217,407...70,221,052
Ensembl chr 3:70,217,385...70,221,050
|
|
G |
Apoa4 |
apolipoprotein A4 |
affects expression |
EXP |
triphenyl phosphate affects the expression of APOA4 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469
|
|
G |
Apoe |
apolipoprotein E |
affects response to substance |
ISO |
APOE protein affects the susceptibility to triphenyl phosphate |
CTD |
PMID:31724879 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
increases expression |
EXP |
triphenyl phosphate results in increased expression of APP mRNA |
CTD |
PMID:30589522 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp7 |
aquaporin 7 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of AQP7 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:56,171,649...56,186,642
Ensembl chr 5:56,172,519...56,186,642
|
|
G |
Aqp9 |
aquaporin 9 |
affects expression |
EXP |
triphenyl phosphate affects the expression of AQP9 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395
|
|
G |
Ar |
androgen receptor |
affects binding decreases activity multiple interactions |
EXP ISO |
triphenyl phosphate binds to AR protein triphenyl phosphate results in decreased activity of AR protein triphenyl phosphate binds to and results in decreased activity of AR protein; triphenyl phosphate inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; triphenyl phosphate inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; triphenyl phosphate metabolite inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein] |
CTD |
PMID:14565775 PMID:23398518 PMID:24051214 PMID:26778350 PMID:28728110 PMID:33049310 More...
|
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arhgap24 |
Rho GTPase activating protein 24 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ARHGAP24 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr14:6,800,631...7,184,001
Ensembl chr14:6,800,631...7,183,823
|
|
G |
Arhgef26 |
Rho guanine nucleotide exchange factor 26 |
affects expression |
EXP |
triphenyl phosphate affects the expression of ARHGEF26 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:146,740,336...146,850,918
Ensembl chr 2:146,739,631...146,850,819
|
|
G |
Arid5b |
AT-rich interaction domain 5B |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ARID5B mRNA |
CTD |
PMID:30589522 |
|
NCBI chr20:20,307,731...20,490,746
Ensembl chr20:20,307,731...20,487,433
|
|
G |
Armc9 |
armadillo repeat containing 9 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ARMC9 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 9:86,802,791...86,928,860
Ensembl chr 9:86,802,868...86,928,860
|
|
G |
Arntl |
aryl hydrocarbon receptor nuclear translocator-like |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ARNTL mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
|
|
G |
Arpp19 |
cAMP-regulated phosphoprotein 19 |
affects expression |
EXP |
triphenyl phosphate affects the expression of ARPP19 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:75,779,640...75,802,474
Ensembl chr 8:75,779,523...75,802,452
|
|
G |
Arsb |
arylsulfatase B |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ARSB mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:25,002,210...25,162,675
Ensembl chr 2:25,002,346...25,162,671
|
|
G |
Arsl |
arylsulfatase L |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ARSL mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:119,038,803...119,047,579
Ensembl chr 2:119,038,921...119,046,846
|
|
G |
Asb5 |
ankyrin repeat and SOCS box-containing 5 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ASB5 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr16:37,237,869...37,305,207
Ensembl chr16:37,235,405...37,278,109
|
|
G |
Asl |
argininosuccinate lyase |
affects expression |
EXP |
triphenyl phosphate affects the expression of ASL mRNA |
CTD |
PMID:30589522 |
|
NCBI chr12:26,659,664...26,677,136
Ensembl chr12:26,659,565...26,679,662
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression multiple interactions |
EXP ISO |
triphenyl phosphate results in increased expression of ASNS mRNA [tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of ASNS mRNA |
CTD |
PMID:30589522 PMID:33367866 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression multiple interactions |
EXP ISO |
triphenyl phosphate results in increased expression of ATF4 mRNA [tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of ATF4 mRNA |
CTD |
PMID:30589522 PMID:33367866 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ATF6 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atoh8 |
atonal bHLH transcription factor 8 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ATOH8 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:104,259,992...104,292,168
Ensembl chr 4:104,259,992...104,292,168
|
|
G |
Atp6v1c2 |
ATPase H+ transporting V1 subunit C2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ATP6V1C2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:40,080,545...40,144,199
Ensembl chr 6:40,080,547...40,120,028
|
|
G |
Atp8a1 |
ATPase phospholipid transporting 8A1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ATP8A1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr14:40,315,013...40,557,572
Ensembl chr14:40,315,049...40,554,611
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
affects expression |
EXP |
triphenyl phosphate affects the expression of ATP8B1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Atrn |
attractin |
affects expression |
EXP |
triphenyl phosphate affects the expression of ATRN mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:118,110,320...118,244,326
Ensembl chr 3:118,110,229...118,244,322
|
|
G |
Aurkb |
aurora kinase B |
affects expression |
EXP |
triphenyl phosphate affects the expression of AURKB mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Avpi1 |
arginine vasopressin-induced 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of AVPI1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:240,930,236...240,936,154
Ensembl chr 1:240,930,236...240,936,154
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of AVPR1A mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215
|
|
G |
Axin2 |
axin 2 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of AXIN2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
Axl |
Axl receptor tyrosine kinase |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of AXL mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:81,265,656...81,296,278
Ensembl chr 1:81,265,088...81,296,265
|
|
G |
B3gnt2 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of B3GNT2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr14:96,808,473...96,833,674
Ensembl chr14:96,806,664...96,835,273
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of BBC3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcar3 |
BCAR3 adaptor protein, NSP family member |
increases expression |
EXP |
triphenyl phosphate results in increased expression of BCAR3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:210,525,260...210,638,674
Ensembl chr 2:210,525,260...210,638,798
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
affects expression |
EXP |
triphenyl phosphate affects the expression of BCL2A1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of BCL2L11 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bcl6b |
BCL6B, transcription repressor |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of BCL6B mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:54,940,908...54,947,022
Ensembl chr10:54,940,909...54,945,974
|
|
G |
Bdh2 |
3-hydroxybutyrate dehydrogenase 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of BDH2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:223,702,410...223,723,076
Ensembl chr 2:223,702,412...223,723,072
|
|
G |
Bgn |
biglycan |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of BGN mRNA |
CTD |
PMID:30589522 |
|
NCBI chr X:151,197,296...151,209,458
Ensembl chr X:151,197,273...151,209,461
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of BHMT mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742
|
|
G |
Blm |
BLM RecQ like helicase |
increases expression |
EXP |
triphenyl phosphate results in increased expression of BLM mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:134,409,832...134,496,073
Ensembl chr 1:134,409,857...134,484,312
|
|
G |
Bpifb4 |
BPI fold containing family B, member 4 |
decreases expression |
ISO |
triphenyl phosphate results in decreased expression of BPIFB4 mRNA |
CTD |
PMID:28934090 |
|
NCBI chr 3:142,423,571...142,448,044
Ensembl chr 3:142,400,976...142,448,044
|
|
G |
Bub1 |
BUB1 mitotic checkpoint serine/threonine kinase |
increases expression |
EXP |
triphenyl phosphate results in increased expression of BUB1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650
|
|
G |
C1qa |
complement C1q A chain |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of C1QA mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534
|
|
G |
C1qc |
complement C1q C chain |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of C1QC mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:149,127,424...149,130,732
Ensembl chr 5:149,127,415...149,131,017
|
|
G |
C3ar1 |
complement C3a receptor 1 |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of C3AR1 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr 4:156,074,747...156,084,680
Ensembl chr 4:156,075,389...156,084,701
|
|
G |
Cabcoco1 |
ciliary associated calcium binding coiled-coil 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CABCOCO1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr20:20,058,492...20,167,973
Ensembl chr20:20,058,454...20,167,725
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
multiple interactions |
ISO |
[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of CACNA1G mRNA; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of CACNA1G mRNA] |
CTD |
PMID:29112739 |
|
NCBI chr10:79,354,998...79,422,960
Ensembl chr10:79,355,008...79,422,752
|
|
G |
Cacna1h |
calcium voltage-gated channel subunit alpha1 H |
multiple interactions |
ISO |
[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of CACNA1H mRNA; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of CACNA1H mRNA] |
CTD |
PMID:29112739 |
|
NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376
|
|
G |
Cacna1i |
calcium voltage-gated channel subunit alpha1 I |
multiple interactions |
ISO |
[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of CACNA1I mRNA; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of CACNA1I mRNA] |
CTD |
PMID:29112739 |
|
NCBI chr 7:111,835,996...111,947,418
Ensembl chr 7:111,836,012...111,944,688
|
|
G |
Cadm1 |
cell adhesion molecule 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CADM1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:47,847,836...48,178,703
Ensembl chr 8:47,847,325...48,182,833
|
|
G |
Calr3 |
calreticulin 3 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CALR3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr16:17,396,064...17,423,166
Ensembl chr16:17,396,247...17,423,015
|
|
G |
Caprin2 |
caprin family member 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CAPRIN2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:181,806,105...181,860,754
Ensembl chr 4:181,806,575...181,860,830
|
|
G |
Car1 |
carbonic anhydrase 1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CA1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208
|
|
G |
Car3 |
carbonic anhydrase 3 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CAR3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
Cartpt |
CART prepropeptide |
multiple interactions |
ISO |
[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of CARTPT mRNA; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of CARTPT mRNA] |
CTD |
PMID:29112739 |
|
NCBI chr 2:31,255,098...31,257,452
Ensembl chr 2:31,255,098...31,290,713
|
|
G |
Casp3 |
caspase 3 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CASP3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CASP4 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Cat |
catalase |
increases expression increases activity |
ISO EXP |
triphenyl phosphate results in increased expression of CAT mRNA; triphenyl phosphate results in increased expression of CAT protein triphenyl phosphate results in increased activity of CAT protein |
CTD |
PMID:26049154 PMID:26183808 PMID:30974155 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cav2 |
caveolin 2 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CAV2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:45,616,766...45,624,144
Ensembl chr 4:45,616,712...45,624,244
|
|
G |
Cbr4 |
carbonyl reductase 4 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CBR4 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr16:28,629,928...28,684,230
Ensembl chr16:28,617,224...28,645,712
|
|
G |
Cbs |
cystathionine beta synthase |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CBS mRNA |
CTD |
PMID:30589522 |
|
NCBI chr20:9,708,089...9,732,623
Ensembl chr20:9,708,090...9,732,764
|
|
G |
Cbx5 |
chromobox 5 |
affects expression |
EXP |
triphenyl phosphate affects the expression of CBX5 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 7:134,333,165...134,376,102
Ensembl chr 7:134,331,335...134,375,022
|
|
G |
Cc2d2a |
coiled-coil and C2 domain containing 2A |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CC2D2A mRNA |
CTD |
PMID:30589522 |
|
NCBI chr14:67,349,004...67,435,883
Ensembl chr14:67,351,353...67,435,949
|
|
G |
Ccdc17 |
coiled-coil domain containing 17 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CCDC17 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:130,051,158...130,056,676
Ensembl chr 5:130,045,938...130,056,673
|
|
G |
Ccdc80 |
coiled-coil domain containing 80 |
affects expression |
EXP |
triphenyl phosphate affects the expression of CCDC80 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr11:55,685,165...55,718,827
Ensembl chr11:55,685,872...55,719,137
|
|
G |
Ccl24 |
C-C motif chemokine ligand 24 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CCL24 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr12:21,100,835...21,104,832
Ensembl chr12:21,100,835...21,104,893
|
|
G |
Ccl6 |
C-C motif chemokine ligand 6 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CCL6 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:68,381,179...68,385,811
Ensembl chr10:68,380,188...68,384,001
|
|
G |
Ccn2 |
cellular communication network factor 2 |
affects expression |
EXP |
triphenyl phosphate affects the expression of CCN2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccng2 |
cyclin G2 |
affects expression |
EXP |
triphenyl phosphate affects the expression of CCNG2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
|
|
G |
Ccser2 |
coiled-coil serine-rich protein 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CCSER2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr16:12,613,103...12,725,764
Ensembl chr16:12,613,103...12,725,738
|
|
G |
Cd163 |
CD163 molecule |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CD163 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:157,085,080...157,118,470
Ensembl chr 4:157,085,093...157,117,878
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of CD36 mRNA; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of CD36 mRNA] |
CTD |
PMID:29112739 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd46 |
CD46 molecule |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CD46 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr13:106,575,586...106,606,325
Ensembl chr13:106,574,858...106,660,445
|
|
G |
Cd5l |
Cd5 molecule-like |
affects expression |
EXP |
triphenyl phosphate affects the expression of CD5L mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:172,791,007...172,802,018
Ensembl chr 2:172,790,934...172,829,753
|
|
G |
Cd74 |
CD74 molecule |
affects expression |
EXP |
triphenyl phosphate affects the expression of CD74 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003
|
|
G |
Cd93 |
CD93 molecule |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CD93 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:135,891,859...135,898,378
Ensembl chr 3:135,891,859...135,898,378
|
|
G |
Cdc25b |
cell division cycle 25B |
affects expression |
EXP |
triphenyl phosphate affects the expression of CDC25B mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:118,407,127...118,417,272
Ensembl chr 3:118,407,128...118,417,272
|
|
G |
Cdc42ep3 |
CDC42 effector protein 3 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CDC42EP3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:15,710,894...15,731,366
Ensembl chr 6:15,708,730...15,732,721
|
|
G |
Cdh5 |
cadherin 5 |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of CDH5 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368
|
|
G |
Cdhr1 |
cadherin-related family member 1 |
increases expression |
ISO |
triphenyl phosphate results in increased expression of CDHR1 mRNA |
CTD |
PMID:28934090 |
|
NCBI chr16:12,843,436...12,863,321
Ensembl chr16:12,843,437...12,863,396
|
|
G |
Cdk14 |
cyclin-dependent kinase 14 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CDK14 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:28,666,688...29,258,865
Ensembl chr 4:28,666,843...29,258,861
|
|
G |
Cdkl2 |
cyclin dependent kinase like 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CDKL2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr14:16,027,381...16,063,257
Ensembl chr14:16,028,363...16,063,252
|
|
G |
Cdkl4 |
cyclin-dependent kinase-like 4 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CDKL4 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:14,449,822...14,492,568
Ensembl chr 6:14,450,681...14,492,046
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CDKN1A mRNA |
CTD |
PMID:30589522 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2aipnl |
CDKN2A interacting protein N-terminal like |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CDKN2AIPNL mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:36,231,134...36,240,569
Ensembl chr10:36,231,087...36,240,564
|
|
G |
Cdt1 |
chromatin licensing and DNA replication factor 1 |
affects expression |
EXP |
triphenyl phosphate affects the expression of CDT1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
affects expression |
EXP |
triphenyl phosphate affects the expression of CEACAM1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
increases expression multiple interactions |
ISO |
triphenyl phosphate results in increased expression of CEBPA mRNA [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate analog] results in increased expression of CEBPA mRNA; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate] results in increased expression of CEBPA mRNA |
CTD |
PMID:28163246 PMID:28437481 PMID:28934090 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression |
ISO |
triphenyl phosphate results in increased expression of CEBPB mRNA |
CTD |
PMID:28163246 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
increases expression affects expression |
ISO EXP |
triphenyl phosphate results in increased expression of CEBPD mRNA triphenyl phosphate affects the expression of CEBPD mRNA |
CTD |
PMID:28163246 PMID:30589522 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Cela1 |
chymotrypsin like elastase 1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CELA1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 7:131,773,161...131,786,300
Ensembl chr 7:131,742,002...131,786,285
|
|
G |
Cenpk |
centromere protein K |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CENPK mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:35,360,132...35,421,372
Ensembl chr 2:35,360,132...35,385,706
|
|
G |
Cenpl |
centromere protein L |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CENPL mRNA |
CTD |
PMID:30589522 |
|
NCBI chr13:73,337,235...73,352,115
Ensembl chr13:73,337,257...73,352,114
|
|
G |
Cep104 |
centrosomal protein 104 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CEP104 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:164,534,773...164,567,260
Ensembl chr 5:164,534,782...164,567,248
|
|
G |
Cep164 |
centrosomal protein 164 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CEP164 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:46,070,901...46,134,511
Ensembl chr 8:46,071,076...46,134,336
|
|
G |
Cers6 |
ceramide synthase 6 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CERS6 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:53,630,636...53,879,692
Ensembl chr 3:53,630,959...53,876,848
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions decreases expression decreases activity |
ISO EXP |
triphenyl phosphate inhibits the reaction [CES1 protein results in increased metabolism of and results in increased activity of imidapril] triphenyl phosphate results in decreased expression of CES1D mRNA triphenyl phosphate results in decreased activity of CES1 protein |
CTD |
PMID:30589522 PMID:31268531 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Cfap20 |
cilia and flagella associated protein 20 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CFAP20 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr19:9,608,851...9,622,562
Ensembl chr19:9,608,859...9,622,558
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CHAC1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526
|
|
G |
Chd9 |
chromodomain helicase DNA binding protein 9 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CHD9 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr19:15,941,535...16,146,220
Ensembl chr19:15,942,687...16,164,556
|
|
G |
Chka |
choline kinase alpha |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CHKA mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:201,076,804...201,125,517
Ensembl chr 1:201,076,860...201,125,516
|
|
G |
Chmp4c |
charged multivesicular body protein 4C |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CHMP4C mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:91,391,729...91,428,652
Ensembl chr 2:91,388,530...91,428,668
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
ISO |
triphenyl phosphate inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]] |
CTD |
PMID:22750351 |
|
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO |
triphenyl phosphate inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]] |
CTD |
PMID:22750351 |
|
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Chsy1 |
chondroitin sulfate synthase 1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CHSY1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:119,689,626...119,750,711
Ensembl chr 1:119,686,350...119,750,601
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CHUK mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cidea |
cell death-inducing DFFA-like effector a |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CIDEA mRNA |
CTD |
PMID:30589522 |
|
NCBI chr18:60,894,917...60,920,485
Ensembl chr18:60,894,874...60,920,481
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
increases expression multiple interactions |
ISO |
triphenyl phosphate results in increased expression of CIDEC mRNA [triphenyl phosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CIDEC mRNA |
CTD |
PMID:28934090 PMID:34323617 |
|
NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
|
|
G |
Cish |
cytokine inducible SH2-containing protein |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CISH mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:107,972,306...107,977,254
Ensembl chr 8:107,972,306...107,977,250
|
|
G |
Clca2 |
chloride channel accessory 2 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CLCA2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:233,993,619...234,022,691
Ensembl chr 2:233,995,078...234,022,199
|
|
G |
Clcf1 |
cardiotrophin-like cytokine factor 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CLCF1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:201,507,763...201,517,607
Ensembl chr 1:201,507,859...201,517,605
|
|
G |
Clcn3 |
chloride voltage-gated channel 3 |
affects expression |
EXP |
triphenyl phosphate affects the expression of CLCN3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr16:29,127,419...29,200,133
Ensembl chr16:29,127,419...29,200,119
|
|
G |
Cldn1 |
claudin 1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CLDN1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Cldn14 |
claudin 14 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CLDN14 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr11:33,232,281...33,329,440
Ensembl chr11:33,232,220...33,329,171
|
|
G |
Clec4f |
C-type lectin domain family 4, member F |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CLEC4F mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:116,129,023...116,138,744
Ensembl chr 4:116,129,023...116,138,775
|
|
G |
Clock |
clock circadian regulator |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CLOCK mRNA |
CTD |
PMID:30589522 |
|
NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400
|
|
G |
Clpx |
caseinolytic mitochondrial matrix peptidase chaperone subunit X |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CLPX mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:65,805,460...65,845,643
Ensembl chr 8:65,805,511...65,845,082
|
|
G |
Cmip |
c-Maf-inducing protein |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CMIP mRNA |
CTD |
PMID:30589522 |
|
NCBI chr19:45,304,597...45,510,653
Ensembl chr19:45,304,031...45,508,709
|
|
G |
Cmtm6 |
CKLF-like MARVEL transmembrane domain containing 6 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CMTM6 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:114,422,681...114,441,034
Ensembl chr 8:114,422,921...114,441,033
|
|
G |
Cmtm8 |
CKLF-like MARVEL transmembrane domain containing 8 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CMTM8 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:114,481,730...114,547,107
Ensembl chr 8:114,481,982...114,547,083
|
|
G |
Cndp2 |
carnosine dipeptidase 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CNDP2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr18:78,039,924...78,057,030
Ensembl chr18:78,039,932...78,056,922
|
|
G |
Cnn1 |
calponin 1 |
decreases expression |
ISO |
triphenyl phosphate results in decreased expression of CNN1 mRNA |
CTD |
PMID:28934090 |
|
NCBI chr 8:20,632,434...20,641,097
Ensembl chr 8:20,632,338...20,641,098
|
|
G |
Cnnm2 |
cyclin and CBS domain divalent metal cation transport mediator 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CNNM2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:245,643,682...245,769,542
Ensembl chr 1:245,643,768...245,763,286
|
|
G |
Cnp |
2',3'-cyclic nucleotide 3' phosphodiesterase |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CNP mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:85,511,164...85,517,723
Ensembl chr10:85,511,160...85,517,720
|
|
G |
Cobl |
cordon-bleu WH2 repeat protein |
increases expression |
EXP |
triphenyl phosphate results in increased expression of COBL mRNA |
CTD |
PMID:30589522 |
|
NCBI chr14:86,828,137...87,060,682
Ensembl chr14:86,828,139...87,060,800
|
|
G |
Cobll1 |
cordon-bleu WH2 repeat protein-like 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of COBLL1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:49,753,260...49,915,168
Ensembl chr 3:49,753,262...49,915,194
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of COL10A1 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494
|
|
G |
Col13a1 |
collagen type XIII alpha 1 chain |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of COL13A1 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr20:29,783,965...29,924,116
Ensembl chr20:29,783,965...29,924,032
|
|
G |
Col14a1 |
collagen type XIV alpha 1 chain |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of COL14A1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 7:86,722,093...86,937,215
Ensembl chr 7:86,722,094...86,937,214
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of COL1A2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Col24a1 |
collagen type XXIV alpha 1 chain |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of COL24A1 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr 2:234,212,256...234,469,445
Ensembl chr 2:234,212,324...234,469,441
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of COL4A1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412
|
|
G |
Col5a1 |
collagen type V alpha 1 chain |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of COL5A1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:11,208,429...11,356,715
Ensembl chr 3:11,208,512...11,354,588
|
|
G |
Col5a2 |
collagen type V alpha 2 chain |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of COL5A2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 9:47,448,736...47,598,396
Ensembl chr 9:47,448,736...47,598,154
|
|
G |
Col6a3 |
collagen type VI alpha 3 chain |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of COL6A3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471
|
|
G |
Colec11 |
collectin sub-family member 11 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of COLEC11 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:45,223,974...45,256,640
Ensembl chr 6:45,223,980...45,271,145
|
|
G |
Copz2 |
COPI coat complex subunit zeta 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of COPZ2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:81,832,441...81,845,514
Ensembl chr10:81,832,418...81,845,514
|
|
G |
Corin |
corin, serine peptidase |
decreases expression |
ISO |
triphenyl phosphate results in decreased expression of CORIN mRNA |
CTD |
PMID:28934090 |
|
NCBI chr14:35,680,601...35,910,703
Ensembl chr14:35,681,304...35,909,503
|
|
G |
Coro1c |
coronin 1C |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CORO1C mRNA |
CTD |
PMID:30589522 |
|
NCBI chr12:42,712,960...42,785,179
Ensembl chr12:42,712,991...42,785,179
|
|
G |
Coro6 |
coronin 6 |
affects expression |
EXP |
triphenyl phosphate affects the expression of CORO6 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:62,311,552...62,319,659
Ensembl chr10:62,311,660...62,319,659
|
|
G |
Cotl1 |
coactosin-like F-actin binding protein 1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of COTL1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr19:47,871,689...47,906,010
Ensembl chr19:47,871,694...47,911,689
|
|
G |
Cpne3 |
copine 3 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CPNE3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:33,014,658...33,064,004
Ensembl chr 5:33,016,307...33,063,934
|
|
G |
Cpne8 |
copine 8 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CPNE8 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 7:121,615,293...121,789,507
Ensembl chr 7:121,615,294...121,790,377
|
|
G |
Cpped1 |
calcineurin-like phosphoesterase domain containing 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CPPED1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:3,701,522...3,821,050
Ensembl chr10:3,701,459...3,821,054
|
|
G |
Cpsf6 |
cleavage and polyadenylation specific factor 6 |
affects expression |
EXP |
triphenyl phosphate affects the expression of CPSF6 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 7:52,956,589...53,001,783
Ensembl chr 7:52,956,589...52,988,122
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
decreases expression affects expression |
ISO EXP |
triphenyl phosphate results in decreased expression of CPT1A mRNA triphenyl phosphate affects the expression of CPT1A mRNA |
CTD |
PMID:30589522 PMID:30966736 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CPT1B mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
increases expression |
ISO |
triphenyl phosphate results in increased expression of CPT2 mRNA |
CTD |
PMID:30966736 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Cptp |
ceramide-1-phosphate transfer protein |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CPTP mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:166,474,947...166,479,103
Ensembl chr 5:166,474,966...166,479,017
|
|
G |
Crat |
carnitine O-acetyltransferase |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CRAT mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:13,675,684...13,689,282
Ensembl chr 3:13,675,684...13,689,255
|
|
G |
Crb3 |
crumbs cell polarity complex component 3 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CRB3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 9:1,898,531...1,903,860
Ensembl chr 9:1,896,623...1,903,859
|
|
G |
Creg1 |
cellular repressor of E1A-stimulated genes 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CREG1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr13:78,019,814...78,032,310
Ensembl chr13:78,019,843...78,032,308
|
|
G |
Crem |
cAMP responsive element modulator |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CREM mRNA |
CTD |
PMID:30589522 |
|
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Crim1 |
cysteine rich transmembrane BMP regulator 1 |
affects expression |
EXP |
triphenyl phosphate affects the expression of CRIM1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:16,695,864...16,870,264
Ensembl chr 6:16,697,829...16,870,259
|
|
G |
Crip2 |
cysteine-rich protein 2 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CRIP2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:132,221,120...132,226,066
Ensembl chr 6:132,221,082...132,226,065
|
|
G |
Crot |
carnitine O-octanoyltransferase |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CROT mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:25,068,270...25,133,111
Ensembl chr 4:25,080,587...25,133,109
|
|
G |
Crppa |
CDP-L-ribitol pyrophosphorylase A |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ISPD mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:53,120,264...53,397,030
Ensembl chr 6:53,121,438...53,397,028
|
|
G |
Cry1 |
cryptochrome circadian regulator 1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CRY1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091
|
|
G |
Cry2 |
cryptochrome circadian regulator 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CRY2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:78,374,995...78,405,001
Ensembl chr 3:78,374,995...78,404,965
|
|
G |
Crybg3 |
crystallin beta-gamma domain containing 3 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CRYBG3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr11:40,749,198...40,861,753
Ensembl chr11:40,749,214...40,861,752
|
|
G |
Cryl1 |
crystallin, lambda 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CRYL1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr15:31,427,011...31,545,997
Ensembl chr15:31,427,054...31,545,997
|
|
G |
Crym |
crystallin, mu |
affects expression |
EXP |
triphenyl phosphate affects the expression of CRYM mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:174,560,423...174,575,660
Ensembl chr 1:174,560,416...174,575,633
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
affects expression multiple interactions |
EXP ISO |
triphenyl phosphate affects the expression of CSF1R mRNA [tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of CSF1R mRNA |
CTD |
PMID:30589522 PMID:33367866 |
|
NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415
|
|
G |
Csnk1d |
casein kinase 1, delta |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CSNK1D mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:106,221,992...106,256,620
Ensembl chr10:106,221,992...106,256,614
|
|
G |
Csrnp1 |
cysteine and serine rich nuclear protein 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CSRNP1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:119,704,712...119,717,767
Ensembl chr 8:119,704,713...119,718,183
|
|
G |
Csrp1 |
cysteine and glycine-rich protein 1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CSRP1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr13:47,158,171...47,179,388
Ensembl chr13:47,167,789...47,179,384
|
|
G |
Ctf1 |
cardiotrophin 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CTF1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:182,328,035...182,336,346
Ensembl chr 1:182,328,090...182,333,335
|
|
G |
Cth |
cystathionine gamma-lyase |
decreases expression multiple interactions |
EXP ISO |
triphenyl phosphate results in decreased expression of CTH mRNA [tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of CTH mRNA |
CTD |
PMID:30589522 PMID:33367866 |
|
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Ctse |
cathepsin E |
affects expression |
EXP |
triphenyl phosphate affects the expression of CTSE mRNA |
CTD |
PMID:30589522 |
|
NCBI chr13:43,091,954...43,114,509
Ensembl chr13:43,092,128...43,114,502
|
|
G |
Cux2 |
cut-like homeobox 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CUX2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr12:34,507,723...34,707,581
Ensembl chr12:34,520,959...34,705,806
|
|
G |
Cxadr |
CXADR, Ig-like cell adhesion molecule |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CXADR mRNA |
CTD |
PMID:30589522 |
|
NCBI chr11:16,982,752...17,030,078
Ensembl chr11:16,982,860...17,030,046
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CXCL11 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
affects expression |
EXP |
triphenyl phosphate affects the expression of CXCR4 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CYBA mRNA |
CTD |
PMID:30589522 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cybb |
cytochrome b-245 beta chain |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CYBB mRNA |
CTD |
PMID:30589522 |
|
NCBI chr X:13,360,583...13,392,517
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyfip2 |
cytoplasmic FMR1 interacting protein 2 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CYFIP2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:30,621,318...30,741,113
Ensembl chr10:30,621,318...30,741,113
|
|
G |
Cyhr1 |
cysteine and histidine rich 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CYHR1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 7:108,377,943...108,380,824
Ensembl chr 7:108,364,381...108,380,021
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
increases expression decreases expression |
ISO |
triphenyl phosphate results in increased expression of CYP11A1 mRNA triphenyl phosphate results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:22446829 PMID:26049154 PMID:26183808 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
ISO |
triphenyl phosphate results in decreased expression of CYP17A1 mRNA triphenyl phosphate inhibits the reaction [CGB3 protein results in increased expression of CYP17A1 mRNA] |
CTD |
PMID:26049154 PMID:26183808 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases expression increases expression |
EXP |
triphenyl phosphate results in decreased expression of CYP1A1 protein triphenyl phosphate results in increased expression of CYP1A1 mRNA |
CTD |
PMID:30589522 PMID:30974155 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CYP1A2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp26b1 |
cytochrome P450, family 26, subfamily b, polypeptide 1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CYP26B1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions increases expression |
ISO EXP |
[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of CYP2B10 mRNA; [tris(1,3-dichloro-2-propyl)phosphate co-treated with Tritolyl Phosphates co-treated with triphenyl phosphate] results in increased expression of CYP2B10 mRNA triphenyl phosphate results in increased expression of CYP2B1 mRNA |
CTD |
PMID:29112739 PMID:30589522 PMID:32360330 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2f4 |
cytochrome P450, family 2, subfamily f, polypeptide 4 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CYP2F4 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:82,416,108...82,429,897
Ensembl chr 1:82,416,130...82,429,896
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CYP2J4 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Cyp2t1 |
cytochrome P450, family 2, subfamily t, polypeptide 1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CYP2T1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:82,446,321...82,451,564
Ensembl chr 1:82,446,921...82,451,563
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CYP4A1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
|
|
G |
Cyp4a2 |
cytochrome P450, family 4, subfamily a, polypeptide 2 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CYP4A2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:128,922,355...128,934,188
Ensembl chr 5:128,923,615...128,934,165
|
|
G |
Cyp4a3 |
cytochrome P450, family 4, subfamily a, polypeptide 3 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of CYP4A3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:129,097,571...129,115,488
Ensembl chr 5:129,097,926...129,115,463
|
|
G |
Cyp4a8 |
cytochrome P450, family 4, subfamily a, polypeptide 8 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CYP4A8 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:128,702,130...128,733,476
Ensembl chr 5:128,702,131...128,733,476
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
affects expression |
EXP |
triphenyl phosphate affects the expression of CYP51 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of CYP7A1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Dab1 |
DAB adaptor protein 1 |
affects expression |
EXP |
triphenyl phosphate affects the expression of DAB1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:118,392,953...119,513,625
Ensembl chr 5:119,140,533...119,510,552
|
|
G |
Dact2 |
dishevelled-binding antagonist of beta-catenin 2 |
affects expression |
EXP |
triphenyl phosphate affects the expression of DACT2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:55,181,023...55,191,026
Ensembl chr 1:55,181,024...55,191,096
|
|
G |
Dap |
death-associated protein |
increases expression |
EXP |
triphenyl phosphate results in increased expression of DAP mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:82,199,206...82,251,771
Ensembl chr 2:82,199,280...82,251,752
|
|
G |
Dapk1 |
death associated protein kinase 1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of DAPK1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991
|
|
G |
Dbp |
D-box binding PAR bZIP transcription factor |
increases expression |
EXP |
triphenyl phosphate results in increased expression of DBP mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:96,175,796...96,180,745
Ensembl chr 1:96,175,440...96,180,745
|
|
G |
Ddah1 |
dimethylarginine dimethylaminohydrolase 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of DDAH1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:234,667,499...234,800,322
Ensembl chr 2:234,667,491...234,799,339
|
|
G |
Ddc |
dopa decarboxylase |
multiple interactions |
EXP |
[triphenyl phosphate co-treated with Flame Retardants] results in decreased expression of DDC mRNA |
CTD |
PMID:32243540 |
|
NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of DDIT3 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of DDIT4 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Ddit4l |
DNA-damage-inducible transcript 4-like |
affects expression |
EXP |
triphenyl phosphate affects the expression of DDIT4L mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:226,128,273...226,131,044
Ensembl chr 2:226,128,276...226,131,375
|
|
G |
Ddx21 |
DExD-box helicase 21 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of DDX21 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr20:30,534,319...30,554,513
Ensembl chr20:30,534,319...30,554,543
|
|
G |
Ddx6 |
DEAD-box helicase 6 |
affects expression |
EXP |
triphenyl phosphate affects the expression of DDX6 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:44,931,127...44,967,773
Ensembl chr 8:44,931,974...44,964,405
|
|
G |
Dedd |
death effector domain-containing |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of DEDD mRNA |
CTD |
PMID:30589522 |
|
NCBI chr13:83,755,874...83,769,982
Ensembl chr13:83,756,108...83,769,332
|
|
G |
Dennd2a |
DENN domain containing 2A |
affects expression |
EXP |
triphenyl phosphate affects the expression of DENND2A mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:68,233,016...68,332,235
Ensembl chr 4:68,233,958...68,332,105
|
|
G |
Depp1 |
DEPP1, autophagy regulator |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of DEPP1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542
|
|
G |
Desi2 |
desumoylating isopeptidase 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of DESI2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr13:89,961,767...90,011,255
Ensembl chr13:89,961,934...90,016,416
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
increases expression multiple interactions |
ISO |
triphenyl phosphate results in increased expression of DGAT2 mRNA [tris(1,3-dichloro-2-propyl)phosphate co-treated with Tritolyl Phosphates co-treated with triphenyl phosphate] affects the expression of DGAT2 mRNA |
CTD |
PMID:30966736 PMID:32360330 |
|
NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428
|
|
G |
Dgkd |
diacylglycerol kinase, delta |
increases expression |
EXP |
triphenyl phosphate results in increased expression of DGKD mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 9:88,516,686...88,607,349
Ensembl chr 9:88,516,715...88,607,345
|
|
G |
Dido1 |
death inducer-obliterator 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of DIDO1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:167,772,535...167,825,894
Ensembl chr 3:167,772,770...167,817,218
|
|
G |
Dipk1a |
divergent protein kinase domain 1A |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FAM69A mRNA |
CTD |
PMID:30589522 |
|
NCBI chr14:1,772,412...1,843,508
Ensembl chr14:1,772,422...1,843,743
|
|
G |
Dipk2a |
divergent protein kinase domain 2A |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of DIPK2A mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:95,070,695...95,089,815
Ensembl chr 8:95,030,279...95,089,815
|
|
G |
Dlg3 |
discs large MAGUK scaffold protein 3 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of DLG3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr X:65,859,653...65,911,887
Ensembl chr X:65,860,172...65,910,322
|
|
G |
Dnajb6 |
DnaJ heat shock protein family (Hsp40) member B6 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of DNAJB6 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:5,452,683...5,556,679
Ensembl chr 4:5,452,683...5,556,659
|
|
G |
Dsc2 |
desmocollin 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of DSC2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr18:11,450,392...11,482,476
Ensembl chr18:11,450,390...11,482,392
|
|
G |
Dut |
deoxyuridine triphosphatase |
increases expression |
EXP |
triphenyl phosphate results in increased expression of DUT mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:112,498,864...112,509,994
Ensembl chr 3:112,498,982...112,510,771
|
|
G |
Dym |
dymeclin |
increases expression |
EXP |
triphenyl phosphate results in increased expression of DYM mRNA |
CTD |
PMID:30589522 |
|
NCBI chr18:68,605,131...68,900,905
Ensembl chr18:68,605,185...68,900,903
|
|
G |
Echdc3 |
enoyl CoA hydratase domain containing 3 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ECHDC3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr17:72,070,697...72,093,519
Ensembl chr17:72,070,668...72,093,516
|
|
G |
Ecm1 |
extracellular matrix protein 1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ECM1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:183,287,491...183,292,729
Ensembl chr 2:183,287,322...183,292,671
|
|
G |
Edem2 |
ER degradation enhancing alpha-mannosidase like protein 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of EDEM2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:144,201,604...144,227,423
Ensembl chr 3:144,201,605...144,227,485
|
|
G |
Eef2k |
eukaryotic elongation factor-2 kinase |
increases expression |
EXP |
triphenyl phosphate results in increased expression of EEF2K mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:175,393,119...175,454,452
Ensembl chr 1:175,393,154...175,455,164
|
|
G |
Efna1 |
ephrin A1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of EFNA1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:174,681,676...174,690,306
Ensembl chr 2:174,681,682...174,690,866
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of EGFR mRNA |
CTD |
PMID:30589522 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egln1 |
egl-9 family hypoxia-inducible factor 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of EGLN1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr19:52,867,914...52,907,169
Ensembl chr19:52,869,486...52,907,777
|
|
G |
Egln3 |
egl-9 family hypoxia-inducible factor 3 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of EGLN3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:71,650,297...71,675,766
Ensembl chr 6:71,650,297...71,675,766
|
|
G |
Egr1 |
early growth response 1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of EGR1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif1a |
eukaryotic translation initiation factor 1A |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of EIF1A mRNA |
CTD |
PMID:30589522 |
|
NCBI chr18:39,325,695...39,338,043
Ensembl chr18:39,325,202...39,338,696
|
|
G |
Eif4ebp3 |
eukaryotic translation initiation factor 4E binding protein 3 |
affects expression |
EXP |
triphenyl phosphate affects the expression of EIF4EBP3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr18:28,263,089...28,268,033
Ensembl chr18:28,162,311...28,268,024
|
|
G |
Elovl3 |
ELOVL fatty acid elongase 3 |
multiple interactions |
ISO |
[triphenyl phosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ELOVL3 mRNA |
CTD |
PMID:34323617 |
|
NCBI chr 1:244,997,287...245,001,115
Ensembl chr 1:244,997,287...245,001,115
|
|
G |
Elovl6 |
ELOVL fatty acid elongase 6 |
affects expression |
EXP |
triphenyl phosphate affects the expression of ELOVL6 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186
|
|
G |
Eml4 |
EMAP like 4 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of EML4 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:11,219,545...11,334,824
Ensembl chr 6:11,219,566...11,334,879
|
|
G |
Enc1 |
ectodermal-neural cortex 1 |
affects expression |
EXP |
triphenyl phosphate affects the expression of ENC1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713
|
|
G |
Entr1 |
endosome associated trafficking regulator 1 |
affects expression |
EXP |
triphenyl phosphate affects the expression of ENTR1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:9,200,967...9,207,688
Ensembl chr 3:9,200,967...9,207,688
|
|
G |
Epb41l1 |
erythrocyte membrane protein band 4.1-like 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of EPB41L1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:144,929,195...145,052,723
Ensembl chr 3:144,984,640...145,052,721
|
|
G |
Epcam |
epithelial cell adhesion molecule |
increases expression |
EXP |
triphenyl phosphate results in increased expression of EPCAM mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127
|
|
G |
Epha2 |
Eph receptor A2 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of EPHA2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:153,605,644...153,634,115
Ensembl chr 5:153,605,644...153,634,117
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of EPHX1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr13:92,714,315...92,744,124
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Eprs |
glutamyl-prolyl-tRNA synthetase |
affects expression |
EXP |
triphenyl phosphate affects the expression of EPRS mRNA |
CTD |
PMID:30589522 |
|
NCBI chr13:96,901,548...96,971,966
Ensembl chr13:96,901,575...96,971,966
|
|
G |
Eps15 |
epidermal growth factor receptor pathway substrate 15 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of EPS15 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:124,045,865...124,146,221
Ensembl chr 5:124,045,926...124,146,221
|
|
G |
Erg28 |
ergosterol biosynthesis 28 homolog |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ERG28 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:105,474,112...105,483,078
Ensembl chr 6:105,474,113...105,483,078
|
|
G |
Eri2 |
ERI1 exoribonuclease family member 2 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ERI2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:174,140,831...174,168,757
Ensembl chr 1:174,141,993...174,168,665
|
|
G |
Errfi1 |
ERBB receptor feedback inhibitor 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ERRFI1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases activity |
ISO |
triphenyl phosphate binds to and results in increased activity of ESR1 protein [tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of ESR1 mRNA; [tris(1,3-dichloro-2-propyl)phosphate co-treated with Tritolyl Phosphates co-treated with triphenyl phosphate] results in increased expression of ESR1 mRNA; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of and results in decreased secretion of INS1 protein]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of and results in decreased secretion of LEP protein]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of CARTPT mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of CD36 mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of CYP4A10 mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of GHSR mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of NPY mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of NR0B2 mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of CACNA1G mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of CACNA1H mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of CACNA1I mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of GHSR mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of INSR mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of KCNQ2 mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of KCNQ3 mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of KCNQ5 mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of KISS1 mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of LEPR mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of TRPC5 mRNA]; ESR1 gene mutant form results in decreased susceptibility to [tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] triphenyl phosphate metabolite results in increased activity of ESR1 protein; triphenyl phosphate results in increased activity of ESR1 protein |
CTD |
PMID:23398518 PMID:24051214 PMID:24844797 PMID:26778350 PMID:28728110 PMID:29112739 PMID:32360330 PMID:33049310 More...
|
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
increases activity multiple interactions |
ISO |
triphenyl phosphate metabolite results in increased activity of ESR2 protein; triphenyl phosphate results in increased activity of ESR2 protein triphenyl phosphate metabolite inhibits the reaction [Estradiol results in increased activity of ESR2 protein] |
CTD |
PMID:26778350 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Etv6 |
ETS variant transcription factor 6 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ETV6 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:166,849,031...167,085,211
Ensembl chr 4:166,847,686...167,084,992
|
|
G |
Evi2b |
ecotropic viral integration site 2B |
affects expression |
EXP |
triphenyl phosphate affects the expression of EVI2B mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:64,472,693...64,474,311
Ensembl chr10:64,471,505...64,481,560
|
|
G |
Exph5 |
exophilin 5 |
affects expression |
EXP |
triphenyl phosphate affects the expression of EXPH5 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:53,698,825...53,775,371
Ensembl chr 8:53,698,852...53,773,169
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions increases expression |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with triphenyl phosphate] results in increased expression of FABP4 mRNA; [triphenyl phosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA 2-chloro-5-nitrobenzanilide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate analog] results in increased expression of FABP4 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate] results in increased expression of FABP4 mRNA]; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate analog] results in increased expression of FABP4 mRNA; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate analog] results in increased expression of FABP4 protein; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate] results in increased expression of FABP4 mRNA; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate] results in increased expression of FABP4 protein triphenyl phosphate results in increased expression of FABP4 mRNA; triphenyl phosphate results in increased expression of FABP4 protein |
CTD |
PMID:25062436 PMID:28437481 PMID:28934090 PMID:34323617 |
|
NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
increases expression decreases expression |
ISO EXP |
triphenyl phosphate results in increased expression of FABP5 mRNA triphenyl phosphate results in decreased expression of FABP5 mRNA |
CTD |
PMID:28934090 PMID:30589522 |
|
NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773
|
|
G |
Fabp7 |
fatty acid binding protein 7 |
affects expression |
EXP |
triphenyl phosphate affects the expression of FABP7 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr20:37,123,193...37,126,725
Ensembl chr20:37,123,193...37,126,880
|
|
G |
Fam102a |
family with sequence similarity 102, member A |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FAM102A mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:15,823,147...15,854,651
Ensembl chr 3:15,823,144...15,854,643
|
|
G |
Fam117a |
family with sequence similarity 117, member A |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FAM117A mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:80,281,408...80,325,343
Ensembl chr10:80,281,408...80,325,343
|
|
G |
Fam117b |
family with sequence similarity 117, member B |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FAM117B mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 9:61,340,291...61,418,531
Ensembl chr 9:61,340,249...61,408,483
|
|
G |
FAM120C |
family with sequence similarity 120C |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FAM120C mRNA |
CTD |
PMID:30589522 |
|
NCBI chr X:20,324,046...20,477,831
Ensembl chr X:20,323,381...20,477,275
|
|
G |
Fam168a |
family with sequence similarity 168, member A |
affects expression |
EXP |
triphenyl phosphate affects the expression of FAM168A mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:155,057,352...155,203,439
Ensembl chr 1:155,057,352...155,201,220
|
|
G |
Fam174c |
family with sequence similarity 174 member C |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FAM174C mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 7:9,531,995...9,533,705
|
|
G |
Fam20c |
FAM20C, golgi associated secretory pathway kinase |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FAM20C mRNA |
CTD |
PMID:30589522 |
|
NCBI chr12:15,826,864...15,885,423
Ensembl chr12:15,826,871...15,884,543
|
|
G |
Fam76a |
family with sequence similarity 76, member A |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FAM76A mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:145,107,491...145,135,734
Ensembl chr 5:145,107,491...145,135,574
|
|
G |
Fam89a |
family with sequence similarity 89, member A |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of FAM89A mRNA |
CTD |
PMID:30589522 |
|
NCBI chr19:52,710,003...52,722,591
Ensembl chr19:52,710,019...52,722,631
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FAS mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fasn |
fatty acid synthase |
increases expression multiple interactions affects expression |
ISO EXP |
triphenyl phosphate results in increased expression of FASN mRNA [tris(1,3-dichloro-2-propyl)phosphate co-treated with Tritolyl Phosphates co-treated with triphenyl phosphate] results in decreased expression of FASN mRNA triphenyl phosphate affects the expression of FASN mRNA |
CTD |
PMID:28163246 PMID:28934090 PMID:30589522 PMID:32360330 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbn1 |
fibrillin 1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of FBN1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:112,554,257...112,750,835
Ensembl chr 3:112,554,925...112,750,889
|
|
G |
Fbxl22 |
F-box and leucine-rich repeat protein 22 |
decreases expression |
ISO |
triphenyl phosphate results in decreased expression of FBXL22 mRNA |
CTD |
PMID:28934090 |
|
NCBI chr 8:67,069,998...67,076,685
Ensembl chr 8:67,069,998...67,076,685
|
|
G |
Fbxo30 |
F-box protein 30 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FBXO30 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:5,655,341...5,671,558
Ensembl chr 1:5,655,339...5,672,441
|
|
G |
Fbxo6 |
F-box protein 6 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of FBXO6 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:158,576,729...158,582,520
Ensembl chr 5:158,576,759...158,582,525
|
|
G |
Fcer1g |
Fc epsilon receptor Ig |
affects expression |
EXP |
triphenyl phosphate affects the expression of FCER1G mRNA |
CTD |
PMID:30589522 |
|
NCBI chr13:83,649,447...83,654,215
Ensembl chr13:83,649,449...83,671,443
|
|
G |
Fcnb |
ficolin B |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of FCN1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:11,393,771...11,402,198
Ensembl chr 3:11,393,739...11,402,151
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FDFT1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of FGF21 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr 1:96,083,495...96,084,738
Ensembl chr 1:96,083,441...96,090,454
|
|
G |
Fgl2 |
fibrinogen-like 2 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of FGL2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:13,710,566...13,716,207
Ensembl chr 4:13,710,575...13,716,207
|
|
G |
Fkbp11 |
FKBP prolyl isomerase 11 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FKBP11 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 7:129,871,870...129,877,760
Ensembl chr 7:129,871,870...129,875,303
|
|
G |
Fktn |
fukutin |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FKTN mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:68,339,803...68,396,412
Ensembl chr 5:68,340,028...68,396,409
|
|
G |
Flcn |
folliculin |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of FLCN mRNA |
CTD |
PMID:33367866 |
|
NCBI chr10:44,588,621...44,607,808
Ensembl chr10:44,588,624...44,607,769
|
|
G |
Flvcr2 |
FLVCR heme transporter 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FLVCR2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:105,408,355...105,472,355
Ensembl chr 6:105,408,339...105,472,353
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
affects expression |
EXP |
triphenyl phosphate affects the expression of FMO1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
|
|
G |
Fn3krp |
fructosamine-3-kinase-related protein |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FN3KRP mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:106,688,404...106,696,290
Ensembl chr10:106,688,439...106,697,134
|
|
G |
Fndc5 |
fibronectin type III domain containing 5 |
increases expression |
ISO |
triphenyl phosphate results in increased expression of FNDC5 mRNA |
CTD |
PMID:28934090 |
|
NCBI chr 5:141,481,593...141,491,257
Ensembl chr 5:141,481,590...141,490,731
|
|
G |
Fnip2 |
folliculin interacting protein 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FNIP2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:164,596,557...164,708,147
Ensembl chr 2:164,598,906...164,707,901
|
|
G |
Foxa1 |
forkhead box A1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FOXA1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:75,099,907...75,136,534
Ensembl chr 6:75,103,503...75,136,188
|
|
G |
Foxa2 |
forkhead box A2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FOXA2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:135,470,123...135,474,326
Ensembl chr 3:135,470,131...135,474,326
|
|
G |
Foxa3 |
forkhead box A3 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of FOXA3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:78,662,067...78,672,321
Ensembl chr 1:78,662,431...78,672,155
|
|
G |
Foxk2 |
forkhead box K2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FOXK2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:106,542,643...106,592,569
Ensembl chr10:106,542,566...106,592,563
|
|
G |
Foxn3 |
forkhead box N3 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of FOXN3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:118,462,018...118,842,442
Ensembl chr 6:118,466,025...118,842,401
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[tris(1,3-dichloro-2-propyl)phosphate co-treated with Tritolyl Phosphates co-treated with triphenyl phosphate] results in increased expression of FOXO1 mRNA |
CTD |
PMID:32360330 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Foxo3 |
forkhead box O3 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FOXO3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Foxp2 |
forkhead box P2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FOXP2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:43,133,827...43,712,442
Ensembl chr 4:43,133,912...43,711,683
|
|
G |
Frat2 |
FRAT regulator of WNT signaling pathway 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FRAT2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:240,654,120...240,656,685
Ensembl chr 1:240,654,137...240,656,517
|
|
G |
Frk |
fyn-related Src family tyrosine kinase |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FRK mRNA |
CTD |
PMID:30589522 |
|
NCBI chr20:38,265,416...38,371,038
Ensembl chr20:38,265,280...38,371,114
|
|
G |
Frs3 |
fibroblast growth factor receptor substrate 3 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FRS3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 9:13,288,559...13,297,285
Ensembl chr 9:13,288,667...13,295,382
|
|
G |
Fsd1l |
fibronectin type III and SPRY domain containing 1-like |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FSD1L mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:68,258,877...68,334,931
Ensembl chr 5:68,258,932...68,334,928
|
|
G |
Fundc2 |
FUN14 domain containing 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of FUNDC2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr18:128,473...138,232
Ensembl chr18:132,248...138,345
|
|
G |
Fus |
Fus RNA binding protein |
affects expression |
EXP |
triphenyl phosphate affects the expression of FUS mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:182,576,479...182,590,417
Ensembl chr 1:182,576,545...182,590,414
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression multiple interactions |
EXP ISO |
triphenyl phosphate results in decreased expression of G6PC1 mRNA [tris(1,3-dichloro-2-propyl)phosphate co-treated with Tritolyl Phosphates co-treated with triphenyl phosphate] results in decreased expression of G6PC mRNA |
CTD |
PMID:30589522 PMID:32360330 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of GABRA1 mRNA |
CTD |
PMID:33078273 |
|
NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of GAD1 mRNA |
CTD |
PMID:33078273 |
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Gad2 |
glutamate decarboxylase 2 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of GAD2 mRNA |
CTD |
PMID:33078273 |
|
NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155
|
|
G |
Gar1 |
GAR1 ribonucleoprotein |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of GAR1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:218,375,231...218,382,509
Ensembl chr 2:218,375,353...218,382,524
|
|
G |
Gas5 |
growth arrest specific 5 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of GAS5 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr13:73,303,611...73,306,932
|
|
G |
Gckr |
glucokinase regulator |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of GCKR mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:25,044,592...25,075,834
Ensembl chr 6:25,045,100...25,075,654
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
affects expression |
EXP |
triphenyl phosphate affects the expression of GCLC mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
EXP |
triphenyl phosphate results in increased expression of GCLM mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gcnt2 |
glucosaminyl (N-acetyl) transferase 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of GCNT2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr17:23,796,859...23,901,625 NCBI chr17:23,866,602...23,868,691
Ensembl chr17:23,796,859...23,901,611
|
|
G |
Gda |
guanine deaminase |
affects expression |
EXP |
triphenyl phosphate affects the expression of GDA mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:218,903,045...218,982,360
Ensembl chr 1:218,906,815...218,982,416
|
|
G |
Gdf15 |
growth differentiation factor 15 |
multiple interactions |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of GDF15 mRNA |
CTD |
PMID:33367866 |
|
NCBI chr16:18,805,312...18,807,893
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gdpd1 |
glycerophosphodiester phosphodiesterase domain containing 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of GDPD1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:71,840,497...71,883,936
Ensembl chr10:71,840,497...71,883,850
|
|
G |
Gfap |
glial fibrillary acidic protein |
affects expression |
EXP |
triphenyl phosphate affects the expression of GFAP mRNA |
CTD |
PMID:33078273 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
affects expression |
EXP |
triphenyl phosphate affects the expression of GGT1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
|
|
G |
Ghrl |
ghrelin and obestatin prepropeptide |
multiple interactions |
ISO |
[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of and results in increased secretion of GHRL protein |
CTD |
PMID:29112739 |
|
NCBI chr 4:146,865,712...146,869,621
Ensembl chr 4:146,865,712...146,869,621
|
|
G |
Ghsr |
growth hormone secretagogue receptor |
multiple interactions |
ISO |
[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of GHSR mRNA; [tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of GHSR mRNA; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of GHSR mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of GHSR mRNA] |
CTD |
PMID:29112739 |
|
NCBI chr 2:110,268,489...110,271,865
Ensembl chr 2:110,268,489...110,271,865
|
|
G |
Glul |
glutamate-ammonia ligase |
affects expression decreases expression |
EXP |
triphenyl phosphate affects the expression of GLUL mRNA triphenyl phosphate results in decreased expression of GLUL mRNA |
CTD |
PMID:30589522 |
|
NCBI chr13:65,969,064...66,035,121
Ensembl chr13:66,025,630...66,035,108
|
|
G |
Gmppb |
GDP-mannose pyrophosphorylase B |
increases expression |
EXP |
triphenyl phosphate results in increased expression of GMPPB mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:108,737,429...108,767,286
Ensembl chr 8:108,693,060...108,767,286
|
|
G |
Gna12 |
G protein subunit alpha 12 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of GNA12 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr12:13,805,580...13,886,255
Ensembl chr12:13,805,698...13,886,255
|
|
G |
Gna14 |
G protein subunit alpha 14 |
affects expression |
EXP |
triphenyl phosphate affects the expression of GNA14 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:213,714,993...213,900,083
Ensembl chr 1:213,716,020...213,897,423
|
|
G |
Gnmt |
glycine N-methyltransferase |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of GNMT mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 9:14,254,675...14,258,028
Ensembl chr 9:14,254,675...14,258,434
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of GOT1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpbar1 |
G protein-coupled bile acid receptor 1 |
increases expression |
ISO |
triphenyl phosphate results in increased expression of GPBAR1 mRNA |
CTD |
PMID:28934090 |
|
NCBI chr 9:75,862,151...75,863,140
Ensembl chr 9:75,860,677...75,863,168
|
|
G |
Gpd1l |
glycerol-3-phosphate dehydrogenase 1-like |
increases expression |
EXP |
triphenyl phosphate results in increased expression of GPD1L mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:114,591,103...114,620,771
Ensembl chr 8:114,588,487...114,620,723
|
|
G |
Gpi |
glucose-6-phosphate isomerase |
increases expression |
EXP |
triphenyl phosphate results in increased expression of GPI mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:86,828,211...86,856,077
Ensembl chr 1:86,828,216...86,856,086
|
|
G |
Gpr146 |
G protein-coupled receptor 146 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of GPR146 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr12:15,251,936...15,267,217
Ensembl chr12:15,251,813...15,267,206
|
|
G |
Gpr180 |
G protein-coupled receptor 180 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of GPR180 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr15:95,195,782...95,224,955
Ensembl chr15:95,199,777...95,228,373
|
|
G |
Gpr19 |
G protein-coupled receptor 19 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of GPR19 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:167,710,944...167,739,232
Ensembl chr 4:167,710,666...167,741,036
|
|
G |
Gpr68 |
G protein-coupled receptor 68 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of GPR68 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:120,135,620...120,166,089
Ensembl chr 6:120,135,436...120,166,089
|
|
G |
Gpsm2 |
G-protein signaling modulator 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of GPSM2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:196,327,149...196,375,322
Ensembl chr 2:196,327,149...196,375,154
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression |
ISO |
triphenyl phosphate results in increased expression of GPX1 mRNA |
CTD |
PMID:26049154 PMID:26183808 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gramd2b |
GRAM domain containing 2B |
increases expression |
EXP |
triphenyl phosphate results in increased expression of GRAMD3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr18:49,884,014...49,981,955
Ensembl chr18:49,884,014...49,981,953
|
|
G |
Gramd4 |
GRAM domain containing 4 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of GRAMD4 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 7:117,150,398...117,224,056
Ensembl chr 7:117,150,374...117,224,053
|
|
G |
Grb7 |
growth factor receptor bound protein 7 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of GRB7 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:83,443,387...83,453,057
Ensembl chr10:83,444,004...83,453,052
|
|
G |
Grem2 |
gremlin 2, DAN family BMP antagonist |
increases expression |
EXP |
triphenyl phosphate results in increased expression of GREM2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr13:86,778,543...86,871,509
Ensembl chr13:86,778,500...86,871,615
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of GRIN1 mRNA |
CTD |
PMID:33078273 |
|
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of GRIN2A mRNA |
CTD |
PMID:33078273 |
|
NCBI chr10:5,630,684...6,043,341
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Grin2c |
glutamate ionotropic receptor NMDA type subunit 2C |
increases expression |
EXP |
triphenyl phosphate results in increased expression of GRIN2C mRNA |
CTD |
PMID:33078273 |
|
NCBI chr10:100,488,430...100,507,083
Ensembl chr10:100,488,431...100,506,427
|
|
G |
Gskip |
GSK3B interacting protein |
increases expression |
EXP |
triphenyl phosphate results in increased expression of GSKIP mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:124,586,087...124,609,106
Ensembl chr 6:124,586,070...124,609,100
|
|
G |
Gsr |
glutathione-disulfide reductase |
increases expression |
EXP |
triphenyl phosphate results in increased expression of GSR mRNA |
CTD |
PMID:30974155 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of GSTA2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of GSTA3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of GSTA4 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
decreases expression increases expression |
ISO |
triphenyl phosphate results in decreased expression of GSTA1 mRNA triphenyl phosphate results in increased expression of GSTA1 mRNA |
CTD |
PMID:26049154 PMID:26183808 |
|
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
affects expression |
EXP |
triphenyl phosphate affects the expression of GSTP1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of GSTT1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
|
|
G |
Gtpbp4 |
GTP binding protein 4 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of GTPBP4 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr17:61,308,033...61,328,184
Ensembl chr17:61,308,014...61,418,009
|
|
G |
Gucy2c |
guanylate cyclase 2C |
affects expression |
EXP |
triphenyl phosphate affects the expression of GUCY2C mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:169,568,505...169,649,092
Ensembl chr 4:169,568,529...169,649,092
|
|
G |
Gyg1 |
glycogenin 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of GYG1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:102,611,888...102,653,916
Ensembl chr 2:102,598,496...102,653,797
|
|
G |
H1f0 |
H1.0 linker histone |
affects expression |
EXP |
triphenyl phosphate affects the expression of H1F0 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 7:110,592,834...110,594,694
Ensembl chr 7:110,592,208...110,594,694
|
|
G |
Hacl1 |
2-hydroxyacyl-CoA lyase 1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of HACL1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr16:6,826,881...6,863,027
Ensembl chr16:6,824,906...6,863,027
|
|
G |
Hal |
histidine ammonia lyase |
affects expression |
EXP |
triphenyl phosphate affects the expression of HAL mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 7:28,007,449...28,037,701
Ensembl chr 7:28,006,972...28,037,701
|
|
G |
Hao2 |
hydroxyacid oxidase 2 |
affects expression |
EXP |
triphenyl phosphate affects the expression of HAO2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:186,200,137...186,232,997
Ensembl chr 2:186,200,504...186,224,425
|
|
G |
Hba-a3 |
hemoglobin alpha, adult chain 3 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of HBA-A3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:15,311,637...15,312,481
Ensembl chr10:15,311,634...15,312,481
|
|
G |
Hbb |
hemoglobin subunit beta |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of HBB mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012
|
|
G |
Hcfc2 |
host cell factor C2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of HCFC2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 7:20,983,986...21,019,826
Ensembl chr 7:20,991,017...21,019,801
|
|
G |
Hdac11 |
histone deacetylase 11 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of HDAC11 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:123,645,873...123,667,407
Ensembl chr 4:123,650,157...123,667,405
|
|
G |
Hdgf |
heparin binding growth factor |
affects expression |
EXP |
triphenyl phosphate affects the expression of HDGF mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:173,370,147...173,379,756
Ensembl chr 2:173,370,465...173,379,747
|
|
G |
Hecw2 |
HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of HECW2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 9:55,359,462...55,753,106
Ensembl chr 9:55,365,203...55,580,327
|
|
G |
Herc3 |
HECT and RLD domain containing E3 ubiquitin protein ligase 3 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of HERC3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:87,952,202...88,042,492
Ensembl chr 4:87,952,274...88,042,488
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of HERPUD1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
|
|
G |
Hhex |
hematopoietically expressed homeobox |
increases expression |
EXP |
triphenyl phosphate results in increased expression of HHEX mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:235,190,455...235,196,042
Ensembl chr 1:235,190,455...235,196,042
|
|
G |
Hibch |
3-hydroxyisobutyryl-CoA hydrolase |
increases expression |
EXP |
triphenyl phosphate results in increased expression of HIBCH mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 9:48,590,097...48,669,896
Ensembl chr 9:48,590,099...48,669,824
|
|
G |
Hist2h2aa3 |
histone cluster 2 H2A family member A3 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of HIST2H2AA3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:183,808,398...183,808,922
|
|
G |
Hlcs |
holocarboxylase synthetase |
increases expression |
EXP |
triphenyl phosphate results in increased expression of HLCS mRNA |
CTD |
PMID:30589522 |
|
NCBI chr11:33,455,806...33,635,197
Ensembl chr11:33,455,809...33,624,222
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
ISO EXP |
triphenyl phosphate results in increased expression of HMGCR mRNA |
CTD |
PMID:30589522 PMID:30966736 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of HMGCS1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of HMOX1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnrnpa2b1 |
heterogeneous nuclear ribonucleoprotein A2/B1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of HNRNPA2B1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:80,534,659...80,545,297
Ensembl chr 4:80,534,651...80,545,249
|
|
G |
Hprt1 |
hypoxanthine phosphoribosyltransferase 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of HPRT1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr X:132,736,175...132,768,149
Ensembl chr X:132,736,096...132,768,154
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
multiple interactions |
EXP |
[triphenyl phosphate co-treated with Flame Retardants] results in decreased expression of HSD11B2 mRNA |
CTD |
PMID:32243540 |
|
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
|
|
G |
Hsd17b13 |
hydroxysteroid (17-beta) dehydrogenase 13 |
decreases expression multiple interactions |
ISO |
triphenyl phosphate results in decreased expression of HSD17B13 mRNA triphenyl phosphate inhibits the reaction [CGB3 protein results in increased expression of HSD17B13 mRNA] |
CTD |
PMID:26049154 PMID:26183808 |
|
NCBI chr14:5,751,697...5,766,809
Ensembl chr14:5,752,132...5,768,166
|
|
G |
Hsd17b2 |
hydroxysteroid (17-beta) dehydrogenase 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of HSD17B2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202
|
|
G |
Hsd17b7 |
hydroxysteroid (17-beta) dehydrogenase 7 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of HSD17B7 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
decreases expression multiple interactions increases expression |
ISO |
triphenyl phosphate results in decreased expression of HSD3B1 mRNA PPARG protein affects the reaction [triphenyl phosphate results in increased expression of HSD3B1 mRNA] |
CTD |
PMID:26049154 PMID:28282128 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hspb11 |
heat shock protein family B (small), member 11 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of HSPB11 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:122,035,588...122,062,421
Ensembl chr 5:122,035,581...122,062,421
|
|
G |
Htatip2 |
HIV-1 Tat interactive protein 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of HTATIP2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:99,473,411...99,488,632
Ensembl chr 1:99,469,245...99,488,629
|
|
G |
Icoslg |
inducible T-cell co-stimulator ligand |
affects expression |
EXP |
triphenyl phosphate affects the expression of ICOSLG mRNA |
CTD |
PMID:30589522 |
|
NCBI chr20:10,600,420...10,610,718
Ensembl chr20:10,600,420...10,610,703
|
|
G |
Id4 |
inhibitor of DNA binding 4, HLH protein |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ID4 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr17:16,389,387...16,391,956
Ensembl chr17:16,389,387...16,392,470
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
affects expression |
EXP |
triphenyl phosphate affects the expression of IDI1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357
|
|
G |
Ifnar2 |
interferon alpha and beta receptor subunit 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of IFNAR2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr11:30,613,576...30,645,958
Ensembl chr11:30,613,767...30,668,124
|
|
G |
Ifngr1 |
interferon gamma receptor 1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of IFNGR1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:14,333,167...14,351,799
Ensembl chr 1:14,333,187...14,351,785
|
|
G |
Ift140 |
intraflagellar transport 140 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of IFT140 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:14,032,665...14,121,682
Ensembl chr10:14,032,648...14,120,433
|
|
G |
Ift81 |
intraflagellar transport 81 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of IFT81 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr12:33,957,744...34,037,164
Ensembl chr12:33,957,806...34,037,057
|
|
G |
Igf1 |
insulin-like growth factor 1 |
decreases expression affects expression |
ISO |
triphenyl phosphate results in decreased expression of IGF1 protein triphenyl phosphate affects the expression of IGF1 mRNA |
CTD |
PMID:29316351 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
increases expression |
ISO |
triphenyl phosphate results in increased expression of IGF1R mRNA |
CTD |
PMID:29316351 |
|
NCBI chr 1:121,549,839...121,838,545
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Igf2 |
insulin-like growth factor 2 |
increases expression |
ISO |
triphenyl phosphate results in increased expression of IGF2 mRNA |
CTD |
PMID:29316351 |
|
NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018
|
|
G |
Igf2r |
insulin-like growth factor 2 receptor |
increases expression |
EXP ISO |
triphenyl phosphate results in increased expression of IGF2R mRNA |
CTD |
PMID:29316351 PMID:30589522 |
|
NCBI chr 1:47,979,109...48,067,501
Ensembl chr 1:47,979,109...48,067,501
|
|
G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of IGFBP2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of IGFBP3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
|
|
G |
Igkc |
immunoglobulin kappa constant |
affects expression |
EXP |
triphenyl phosphate affects the expression of IGKC mRNA |
CTD |
PMID:30589522 |
|
|
|
G |
Il15 |
interleukin 15 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of IL15 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr19:25,640,013...25,706,818
Ensembl chr19:25,640,251...25,706,820
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of IL1R1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
|
|
G |
Il36b |
interleukin 36, beta |
increases expression |
EXP |
triphenyl phosphate results in increased expression of IL36B mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:7,024,862...7,122,489
Ensembl chr 3:7,021,973...7,031,619
|
|
G |
Inhba |
inhibin subunit beta A |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of INHBA mRNA |
CTD |
PMID:30589522 |
|
NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982
|
|
G |
Inmt |
indolethylamine N-methyltransferase |
affects expression |
EXP |
triphenyl phosphate affects the expression of INMT mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:84,318,197...84,322,493
Ensembl chr 4:84,318,197...84,322,493
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [triphenyl phosphate promotes the reaction [INS protein results in increased import of Glucose]]; triphenyl phosphate promotes the reaction [INS protein results in increased import of Glucose] 2-chloro-5-nitrobenzanilide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate analog] results in increased expression of FABP4 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate] results in increased expression of FABP4 mRNA]; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate analog] results in increased expression of CEBPA mRNA; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate analog] results in increased expression of FABP4 mRNA; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate analog] results in increased expression of FABP4 protein; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate analog] results in increased expression of LPL mRNA; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate analog] results in increased expression of LPL protein; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate analog] results in increased expression of PLIN1 mRNA; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate analog] results in increased expression of PLIN1 protein; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate analog] results in increased expression of PPARG mRNA; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate] results in increased expression of CEBPA mRNA; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate] results in increased expression of FABP4 mRNA; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate] results in increased expression of FABP4 protein; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate] results in increased expression of LPL mRNA; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate] results in increased expression of LPL protein; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate] results in increased expression of PLIN1 mRNA; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate] results in increased expression of PLIN1 protein; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with triphenyl phosphate] results in increased expression of PPARG mRNA |
CTD |
PMID:28163246 PMID:28437481 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Insig1 |
insulin induced gene 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of INSIG1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Insig2 |
insulin induced gene 2 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of INSIG2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr13:32,472,390...32,500,139
Ensembl chr13:32,473,742...32,494,923
|
|
G |
Insr |
insulin receptor |
multiple interactions increases expression |
ISO |
[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of INSR mRNA; [tris(1,3-dichloro-2-propyl)phosphate co-treated with Tritolyl Phosphates co-treated with triphenyl phosphate] results in decreased expression of INSR mRNA; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of INSR mRNA] triphenyl phosphate results in increased expression of INSR mRNA |
CTD |
PMID:29112739 PMID:29316351 PMID:32360330 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Ints6 |
integrator complex subunit 6 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of INTS6 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr15:36,908,966...37,048,043
Ensembl chr15:36,933,724...37,021,527
|
|
G |
Ipp |
intracisternal A particle-promoted polypeptide |
increases expression |
EXP |
triphenyl phosphate results in increased expression of IPP mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:129,962,528...130,001,237
Ensembl chr 5:129,962,643...130,001,242
|
|
G |
Irak1bp1 |
interleukin-1 receptor-associated kinase 1 binding protein 1 |
affects expression |
EXP |
triphenyl phosphate affects the expression of IRAK1BP1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:83,731,512...83,748,289
Ensembl chr 8:83,731,507...83,748,289
|
|
G |
Irak3 |
interleukin-1 receptor-associated kinase 3 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of IRAK3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 7:55,653,949...55,714,371
Ensembl chr 7:55,653,962...55,713,121
|
|
G |
Irf1 |
interferon regulatory factor 1 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of IRF1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166
|
|
G |
Irs1 |
insulin receptor substrate 1 |
increases expression |
ISO |
triphenyl phosphate results in increased expression of IRS1 mRNA |
CTD |
PMID:29316351 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Irs2 |
insulin receptor substrate 2 |
affects expression |
ISO EXP |
triphenyl phosphate affects the expression of IRS2 mRNA |
CTD |
PMID:29316351 PMID:30589522 |
|
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Irx1 |
iroquois homeobox 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of IRX1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:31,294,615...31,300,444
Ensembl chr 1:31,294,615...31,300,444
|
|
G |
Isg20 |
interferon stimulated exonuclease gene 20 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ISG20 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:132,829,303...132,837,027
Ensembl chr 1:132,815,123...132,837,027
|
|
G |
Isyna1 |
inositol-3-phosphate synthase 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ISYNA1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr16:18,839,143...18,841,979
Ensembl chr16:18,839,145...18,841,979
|
|
G |
Itgb2 |
integrin subunit beta 2 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of ITGB2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Itih1 |
inter-alpha trypsin inhibitor, heavy chain 1 |
increases expression |
ISO |
triphenyl phosphate results in increased expression of ITIH1 mRNA |
CTD |
PMID:28934090 |
|
NCBI chr16:6,122,246...6,136,363
Ensembl chr16:6,122,248...6,136,363
|
|
G |
Itih5 |
inter-alpha-trypsin inhibitor heavy chain 5 |
increases expression |
ISO |
triphenyl phosphate results in increased expression of ITIH5 mRNA |
CTD |
PMID:28934090 |
|
NCBI chr17:68,248,115...68,352,216
Ensembl chr17:68,252,128...68,352,207
|
|
G |
Itsn2 |
intersectin 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of ITSN2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:27,616,645...27,727,373
Ensembl chr 6:27,600,406...27,727,124
|
|
G |
Jade1 |
jade family PHD finger 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of JADE1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:124,543,259...124,596,361
Ensembl chr 2:124,543,286...124,596,354
|
|
G |
Jcad |
junctional cadherin 5 associated |
affects expression |
EXP |
triphenyl phosphate affects the expression of JCAD mRNA |
CTD |
PMID:30589522 |
|
NCBI chr17:53,089,382...53,130,996
Ensembl chr17:53,089,382...53,130,967
|
|
G |
Jchain |
joining chain of multimeric IgA and IgM |
affects expression |
EXP |
triphenyl phosphate affects the expression of JCHAIN mRNA |
CTD |
PMID:30589522 |
|
NCBI chr14:19,538,560...19,546,384
Ensembl chr14:19,538,952...19,546,298
|
|
G |
Jpt2 |
Jupiter microtubule associated homolog 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of HN1L mRNA |
CTD |
PMID:30589522 |
|
NCBI chr10:13,963,135...13,983,212
Ensembl chr10:13,963,137...13,983,170
|
|
G |
Kank2 |
KN motif and ankyrin repeat domains 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of KANK2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:20,311,676...20,341,107
Ensembl chr 8:20,311,676...20,340,900
|
|
G |
Kcnq2 |
potassium voltage-gated channel subfamily Q member 2 |
multiple interactions |
ISO |
[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of KCNQ2 mRNA; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of KCNQ2 mRNA] |
CTD |
PMID:29112739 |
|
NCBI chr 3:168,194,776...168,253,831
Ensembl chr 3:168,195,357...168,275,071
|
|
G |
Kcnq3 |
potassium voltage-gated channel subfamily Q member 3 |
multiple interactions |
ISO |
[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of KCNQ3 mRNA; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of KCNQ3 mRNA] |
CTD |
PMID:29112739 |
|
NCBI chr 7:97,730,219...98,025,652
Ensembl chr 7:97,730,465...98,025,653
|
|
G |
Kcnq5 |
potassium voltage-gated channel subfamily Q member 5 |
multiple interactions |
ISO |
[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of KCNQ5 mRNA; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of KCNQ5 mRNA] |
CTD |
PMID:29112739 |
|
NCBI chr 9:23,830,185...24,395,984
Ensembl chr 9:23,833,087...24,394,704
|
|
G |
Khnyn |
KH and NYN domain containing |
increases expression |
EXP |
triphenyl phosphate results in increased expression of KHNYN mRNA |
CTD |
PMID:30589522 |
|
NCBI chr15:29,365,399...29,379,650
Ensembl chr15:29,365,260...29,376,967
|
|
G |
Kif11 |
kinesin family member 11 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of KIF11 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:235,124,371...235,176,760
Ensembl chr 1:235,124,316...235,176,766
|
|
G |
Kif20b |
kinesin family member 20B |
increases expression |
EXP |
triphenyl phosphate results in increased expression of KIF20B mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:232,428,293...232,483,798
Ensembl chr 1:232,428,371...232,483,787
|
|
G |
Kif21a |
kinesin family member 21A |
increases expression |
EXP |
triphenyl phosphate results in increased expression of KIF21A mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 7:122,062,523...122,179,051
Ensembl chr 7:122,062,537...122,178,999
|
|
G |
Kif23 |
kinesin family member 23 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of KIF23 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 8:62,397,908...62,425,162
Ensembl chr 8:62,397,948...62,425,072
|
|
G |
Kiss1 |
KiSS-1 metastasis-suppressor |
multiple interactions |
ISO |
[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of KISS1 mRNA; [tris(1,3-dichloro-2-propyl)phosphate co-treated with Tritolyl Phosphates co-treated with triphenyl phosphate] results in decreased expression of KISS1 mRNA; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of KISS1 mRNA] |
CTD |
PMID:29112739 PMID:32360330 |
|
NCBI chr13:44,774,823...44,780,707
Ensembl chr13:44,774,823...44,780,612
|
|
G |
Klf11 |
Kruppel-like factor 11 |
affects expression |
EXP |
triphenyl phosphate affects the expression of KLF11 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:41,285,699...41,297,548
Ensembl chr 6:41,285,842...41,297,550
|
|
G |
Klf13 |
Kruppel-like factor 13 |
affects expression |
EXP |
triphenyl phosphate affects the expression of KLF13 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 1:117,505,857...117,536,626
Ensembl chr 1:117,503,602...117,551,227
|
|
G |
Klf15 |
Kruppel-like factor 15 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of KLF15 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:122,965,718...122,978,403
Ensembl chr 4:122,965,807...122,978,374
|
|
G |
Klf16 |
Kruppel-like factor 16 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of KLF16 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 7:9,138,503...9,148,322
Ensembl chr 7:9,138,503...9,148,317
|
|
G |
Klf6 |
Kruppel-like factor 6 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of KLF6 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Klhdc8a |
kelch domain containing 8A |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of KLHDC8A mRNA |
CTD |
PMID:30589522 |
|
NCBI chr13:43,735,702...43,744,277
Ensembl chr13:43,736,192...43,744,277
|
|
G |
Kmt5a |
lysine methyltransferase 5A |
affects expression |
EXP |
triphenyl phosphate affects the expression of KMT5A mRNA |
CTD |
PMID:30589522 |
|
NCBI chr12:32,139,353...32,167,777
Ensembl chr12:32,139,178...32,162,711
|
|
G |
Krcc1 |
lysine-rich coiled-coil 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of KRCC1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 4:103,261,566...103,274,672
Ensembl chr 4:103,261,536...103,277,156
|
|
G |
Krt18 |
keratin 18 |
decreases expression |
ISO |
triphenyl phosphate results in decreased expression of KRT18 mRNA |
CTD |
PMID:28934090 |
|
NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
|
|
G |
Kyat1 |
kynurenine aminotransferase 1 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of KYAT1 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:13,459,598...13,493,308
Ensembl chr 3:13,459,591...13,493,355
|
|
G |
Kynu |
kynureninase |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of KYNU mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488
|
|
G |
L3hypdh |
trans-L-3-hydroxyproline dehydratase |
increases expression |
EXP |
triphenyl phosphate results in increased expression of L3HYPDH mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 6:90,636,310...90,647,106
Ensembl chr 6:90,636,310...90,647,106
|
|
G |
Lactb2 |
lactamase, beta 2 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of LACTB2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:5,569,080...5,591,843
Ensembl chr 5:5,569,067...5,596,429
|
|
G |
Lama3 |
laminin subunit alpha 3 |
increases expression |
EXP |
triphenyl phosphate results in increased expression of LAMA3 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr18:3,523,168...3,751,722
Ensembl chr18:3,523,133...3,751,353
|
|
G |
Laptm5 |
lysosomal protein transmembrane 5 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of LAPTM5 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 5:143,087,759...143,109,807
Ensembl chr 5:143,087,759...143,109,807
|
|
G |
Larp1b |
La ribonucleoprotein 1B |
affects expression |
EXP |
triphenyl phosphate affects the expression of LARP1B mRNA |
CTD |
PMID:30589522 |
|
NCBI chr 2:123,936,074...123,969,254
Ensembl chr 2:123,935,983...123,968,896
|
|
G |
Ldhd |
lactate dehydrogenase D |
increases expression |
EXP |
triphenyl phosphate results in increased expression of LDHD mRNA |
CTD |
PMID:30589522 |
|
NCBI chr19:39,573,621...39,595,575
Ensembl chr19:39,573,621...39,595,575
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression decreases expression |
ISO |
triphenyl phosphate results in increased expression of LDLR mRNA triphenyl phosphate results in decreased expression of LDLR mRNA |
CTD |
PMID:26049154 PMID:26183808 PMID:28934090 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lect2 |
leukocyte cell-derived chemotaxin 2 |
decreases expression |
EXP |
triphenyl phosphate results in decreased expression of LECT2 mRNA |
CTD |
PMID:30589522 |
|
NCBI chr17:8,044,759...8,050,983
Ensembl chr17:8,044,759...8,050,983
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of and results in decreased secretion of LEP protein; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of and results in decreased secretion of LEP protein] |
CTD |
PMID:29112739 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57, | |